ImmunoPrecise Antibodies (IPA) 20-F 29 Jul 24 2024 FY Annual report (foreign) Financial data

Cover Page

Cover Page	12 Months Ended
	Apr. 30, 2024 shares
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Apr. 30, 2024
Document Fiscal Year Focus	2024
Document Transition Report	false
Document Shell Company Report	false
Document Fiscal Period Focus	FY
Entity Filer Category	Non-accelerated Filer
Entity Registrant Name	ImmunoPrecise Antibodies Ltd.
Entity Central Index Key	0001715925
Entity File Number	001-39530
Entity Shell Company	false
Entity Voluntary Filers	No
Current Fiscal Year End Date	--04-30
Document Accounting Standard	International Financial Reporting Standards
Entity Incorporation, State or Country Code	A1
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Address, Address Line One	3204 - 4464 Markham Street
Entity Address, City or Town	Victoria
Entity Address, State or Province	BC
Entity Address, Postal Zip Code	V8Z 7X8
Entity Address, Country	CA
Entity Well-known Seasoned Issuer	No
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	IPA
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding	26,944,500
Entity Interactive Data Current	Yes
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Document Annual Report	true
Document Registration Statement	false
Auditor Name	Grant Thornton LLP
Auditor Firm ID	248
Auditor Location	Houston, Texas
Business Contact [Member]
Document Information [Line Items]
Contact Personnel Name	Kristin Taylor
Entity Address, Address Line One	3204 - 4464 Markham Street
Entity Address, City or Town	Victoria
Entity Address, State or Province	BC
Contact Personnel Email Address	ktaylor@ipatherapeutics.com
Entity Address, Postal Zip Code	V8Z 7X8
Entity Address, Country	CA
City Area Code	701
Local Phone Number	404-1043

Consolidated Statements of Fina

Consolidated Statements of Financial Position - CAD ($) $ in Thousands	Apr. 30, 2024	Apr. 30, 2023
Current assets
Cash	$ 3,459	$ 8,280
Amounts receivable, net	3,790	3,247
Tax receivable	414	536
Inventory	2,139	2,060
Unbilled revenue	277	632
Prepaid expenses	1,408	2,037
Total current assets	11,487	16,792
Restricted cash	86	86
Deposit on equipment	475	332
Investment at fair value through profit and loss	0	115
Property and equipment	16,696	10,392
Intangible assets	23,557	30,925
Goodwill	7,687	19,171
Total assets	59,988	77,813
Current liabilities
Accounts payable and accrued liabilities	4,372	3,386
Deferred revenue	1,352	977
Tax payable	553	2
Leases	1,563	1,116
Deferred acquisition payments	284	439
Current liabilities	8,124	5,920
Leases	12,118	6,151
Deferred acquisition payments	0	278
Deferred income tax liability	5,825	7,661
Total liabilities	26,067	20,010
SHAREHOLDERS' EQUITY
Share capital	119,773	117,470
Contributed surplus	12,388	10,796
Accumulated other comprehensive income (loss)	2,025	2,625
Accumulated deficit	(100,265)	(73,088)
Equity	33,921	57,803
Total liabilities and shareholders' equity	$ 59,988	$ 77,813

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
Profit or loss [abstract]
REVENUE	$ 24,518	$ 20,665	$ 19,364
COST OF SALES	12,465	9,102	8,381
GROSS PROFIT	12,053	11,563	10,983
EXPENSES
Research and development	4,043	14,101	7,663
Sales and marketing	3,543	3,608	2,678
General and administrative	15,592	15,383	15,377
Impairment of goodwill	11,161	2,460	0
Impairment of intangible assets	3,870	0	0
Amortization of intangible assets	2,968	4,414	2,013
Total expenses	41,177	39,966	27,731
Loss before other income (expenses) and income taxes	(29,124)	(28,403)	(16,748)
OTHER INCOME (EXPENSES)
Accretion	(19)	(30)	(85)
Grant and subsidy income	331	332	75
Interest and other income	23	122	279
Unrealized foreign exchange gain	86	227	631
Other income (expenses)	421	651	900
Loss before income taxes	(28,703)	(27,752)	(15,848)
Income taxes	1,526	1,192	(861)
NET LOSS FOR THE YEAR	(27,177)	(26,560)	(16,709)
Items that will be reclassified subsequently to loss
Exchange difference on translating foreign operations	(600)	5,104	(1,792)
COMPREHENSIVE LOSS FOR THE YEAR	$ (27,777)	$ (21,456)	$ (18,501)
LOSS PER SHARE - BASIC	$ (1.06)	$ (1.07)	$ (0.85)
LOSS PER SHARE - DILUTED	$ (1.06)	$ (1.07)	$ (0.85)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING	25,635,526	24,897,185	19,688,487

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - CAD ($) $ in Thousands	Total	IPA Europe	BioStrand B.V.	Share Capital	Share Capital IPA Europe	Share Capital BioStrand B.V.	Convertible Debentures-Equity Component	Contributed Surplus	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit
Beginning balance at Apr. 30, 2021	$ 56,924			$ 80,102			$ 127	$ 7,201	$ (687)	$ (29,819)
Beginning balance, shares at Apr. 30, 2021	19,169,216
Shares issued pursuant to deferred acquisition		$ 503	$ 29,122		$ 503	$ 29,122
Shares issued pursuant to deferred acquisition, shares		41,488	4,077,774
Shares issued pursuant to option exercise	$ 612			1,013				(401)
Shares issued pursuant to option exercise, shares	188,000
Shares issued pursuant to warrant exercise	$ 3,238			3,491				(253)
Shares issued pursuant to warrant exercise, shares	925,076
Shares issued pursuant to conversion of convertible debentures	$ 304			328			(24)
Shares issued pursuant to conversion of convertible debentures, shares	75,292
Share-based payments expense	$ 3,083							3,083
Comprehensive income (loss) for the period	(18,501)								(1,792)	(16,709)
Ending balance at Apr. 30, 2022	$ 75,285			114,559			103	9,630	(2,479)	(46,528)
Ending balance, shares at Apr. 30, 2022	24,476,846
Shares issued pursuant to option exercise	$ 716			1,493				(777)
Shares issued pursuant to option exercise, shares	263,537
Shares issued pursuant to conversion of convertible debentures	$ 1,315			1,418			$ (103)
Shares issued pursuant to conversion of convertible debentures, shares	309,877
Share-based payments expense	$ 1,943							1,943
Comprehensive income (loss) for the period	(21,456)								5,104	(26,560)
Ending balance at Apr. 30, 2023	$ 57,803			117,470				10,796	2,625	(73,088)
Ending balance, shares at Apr. 30, 2023	25,050,260
Share-based payments expense	$ 1,535							1,535
Shares issued pursuant to issuance of common shares	$ 2,360			2,303				57
Shares issued pursuant to issuance of common shares, Shares	1,894,240
Comprehensive income (loss) for the period	$ (27,777)								(600)	(27,177)
Ending balance at Apr. 30, 2024	$ 33,921			$ 119,773				$ 12,388	$ 2,025	$ (100,265)
Ending balance, shares at Apr. 30, 2024	26,944,500

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
Operating activities:
Net loss for the period	$ (27,177)	$ (26,560)	$ (16,709)
Items not affecting cash:
Accretion	19	30	85
Amortization and depreciation	5,735	6,685	3,769
Asset impairment	15,031	2,460	167
Deferred income taxes	(1,773)	(926)	(336)
Foreign exchange	15	(146)	(519)
Gain on investment	(2)	(43)	(43)
Share-based payments	1,535	1,943	3,083
Items not affecting cash	(6,617)	(16,557)	(10,503)
Amounts receivable	(601)	(561)	163
Inventory	(102)	(185)	(501)
Unbilled revenue	360	21	91
Prepaid expenses	624	90	(772)
Accounts payable and accrued liabilities	983	(1,665)	1,462
Sales and income taxes payable and receivable	733	(896)	152
Deferred revenue	374	(80)	(13)
Net cash used in operating activities	(4,246)	(19,833)	(9,921)
Investing activities:
Purchase of equipment	(1,397)	(1,495)	(1,066)
Security depost on leases	(141)	40	(259)
Purchase of BioStrand	0	0	(3,692)
Purchase of customer list	0	0	(191)
Deferred acquisition payment	(146)	(592)	0
Sale of QVQ Holdings BV shares	121	80	0
Net cash used in investing activities	(1,563)	(1,967)	(5,208)
Financing activities:
Proceeds on share issuance, net of transaction costs	2,360	716	3,850
Share issue cost pursuant to the acquisition of BioStrand	0	0	(5)
Repayment of leases	(1,339)	(1,337)	(962)
Net cash provided by (used in) financing activities	1,021	(621)	2,883
Decrease in cash during the period	(4,788)	(22,421)	(12,246)
Foreign exchange	(33)	740	455
Cash – beginning of the year	8,366	30,047	41,838
Cash – end of the year	3,545	8,366	30,047
Cash is comprised of:
Cash	3,459	8,280	29,965
Restricted cash	86	86	82
Cash paid for interest	0	263	38
Cash paid for income tax	$ 0	$ 591	$ 1,185

Nature of Operations

Nature of Operations	12 Months Ended
	Apr. 30, 2024
Disclosure Of Nature Of Operations [Abstract]
Nature Of Operations	1. NATURE OF OPERATIONS ImmunoPrecise Antibodies Ltd. (the "Company" or “IPA”) was incorporated under the laws of Alberta on November 22, 1983. The Company is listed on the NASDAQ Global Market (“Nasdaq”) under the trading ticker symbol “IPA.” The Company is a supplier of custom antibody discovery services. The address of the Company's corporate office is 3204 – 4464 Markham Street, Victoria, BC, Canada V8Z 7X8. Going concern basis The consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern. The Company has incurred net losses since its inception, including $ 27.2 million for the year ended April 30, 2024, and has accumulated a deficit of $ 100.3 million as of April 30, 2024. The Company had $ 3.5 million cash on hand as of April 30, 2024. The Company expects its cash on hand as of April 30, 2024 will be insufficient to fund the Company’s operations for at least one year from the date these financial statements are available to be issued. These conditions raise material uncertainties which cast significant doubt as to whether the Company will be able to continue as a going concern should it not be able to obtain financing necessary to fund its planned revenue growth and working capital requirements. The Company will need to raise additional funds to finance its operations and strategic goals and there can be no assurances that sufficient funding, including adequate financing, will be available. The ability of the Company to arrange additional financing in the future depends in part on the prevailing capital market conditions and profitability of its operations. If the Company is unable to raise sufficient funds, reductions in expenditures will be required, and this may impact the future growth plans of the Company.

Basis of Presentation

Basis of Presentation	12 Months Ended
	Apr. 30, 2024
Basis Of Accounting [Abstract]
BASIS OF PRESENTATION	2. BASIS OF PRESENTATION (a) Statement of compliance These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board ("IASB"), and include the significant accounting policies as described in Note 3. Certain items have been reclassified in the prior year financial statements to conform to the presentation and classification used in the current year. These reclassifications had no effect on the Company's consolidated operating results, financial position or cash flows. These consolidated financial statements were approved by the Board of Directors. (b) Basis of measurement These consolidated financial statements have been prepared on the historical cost basis. In addition, these consolidated financial statements have been prepared using the accrual basis of accounting, except for cashflow information. (c) Basis of consolidation These consolidated financial statements include the financial statements of the Company and the following subsidiaries which are wholly owned and subject to control by the Company: Name of Subsidiary % Equity Country of Functional Currency ImmunoPrecise Antibodies (Canada) Ltd. 100 % Canada Canadian dollar ImmunoPrecise Antibodies (USA) Ltd. ("IPA USA") 100 % USA US dollar ImmunoPrecise Antibodies (N.D.) Ltd. 100 % USA US dollar ImmunoPrecise Antibodies (MA) LLC 100 % USA US dollar Talem Therapeutics LLC ("Talem") 100 % USA US dollar ImmunoPrecise Netherlands B.V. 100 % Netherlands Euro ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe") 100 % Netherlands Euro BioStrand B.V. 100 % Belgium Euro Idea Family B.V. 100 % Belgium Euro BioKey B.V. 100 % Belgium Euro BioClue B.V. 100 % Belgium Euro ImmunoPrecise Antibodies (Quebec), Ltd. 100 % Canada Canadian dollar 9438-9244 Quebec, Inc. 100 % Canada Canadian dollar Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with an entity and has the ability to affect those returns through its power over the investee. Subsidiaries are fully consolidated from the date on which control is obtained and continue to be consolidated until the date that such control ceases. Intercompany balances, transactions and unrealized intercompany gains and losses are eliminated upon consolidation. (d) Functional and presentation currency The functional currency of a company is the currency of the primary economic environment in which the company operates. The presentation currency for a company is the currency in which the company chooses to present its financial statements. The presentation currency of the Company is the Canadian dollar. Foreign currency translation Entities whose functional currencies differ from the presentation currency are translated into Canadian dollars as follows: assets and liabilities – at the closing rate as at the reporting date, and income and expenses – at the average rate of the period. All resulting changes are recognized in other comprehensive income as cumulative translation differences. Foreign currency transactions Transactions in foreign currencies are translated into the functional currency at exchange rates at the date of the transactions. Foreign currency monetary assets and liabilities are translated at the functional currency exchange rate at the reporting date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using exchange rates as at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined. All gains and losses on translation of these foreign currency transactions are included in profit or loss. When the Company disposes of its entire interest in a foreign operation, or loses control, joint control, or significant influence over a foreign operation, the foreign currency gains or losses accumulated in other comprehensive income related to the foreign operation are recognized in profit or loss. If an entity disposes of part of an interest in a foreign operation which remains a subsidiary, a proportionate amount of foreign currency gains or losses accumulated in other comprehensive income related to the subsidiary are reallocated between controlling and non-controlling interests.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Apr. 30, 2024
Disclosure Of Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	3. SIGNIFICANT ACCOUNTING POLICIES Business combinations Acquisitions of businesses are accounted for using the acquisition model. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition-date fair values of the assets transferred by the Company, liabilities incurred by the Company to the former owners of the acquiree and the equity interests issued by the Company in exchange for control of the acquiree. Acquisition-related costs are recognized in profit or loss as incurred. At the acquisition date, the identifiable assets acquired, and the liabilities assumed are recognized at their fair value at the acquisition date. Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the acquisition-date amounts of the identifiable assets acquired and the liabilities assumed. If, after reassessment, the net of the acquisition-date amounts of the identifiable assets acquired and liabilities assumed exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer's previously held interest in the acquiree (if any), the excess is recognized immediately in profit or loss as a bargain purchase gain. When the consideration transferred by the Company in a business combination includes assets or liabilities resulting from a contingent consideration arrangement, the contingent consideration is measured at its acquisition-date fair value and included as part of the consideration transferred in a business combination. Changes in the fair value of the contingent consideration that qualify as measurement period adjustments are adjusted retrospectively, with corresponding adjustments against goodwill. Measurement period adjustments are adjustments that arise from additional information obtained during the ‘measurement period’ (which cannot exceed one year from the acquisition date) about facts and circumstances that existed at the acquisition date. Revenue recognition The Company recognizes revenue from sale of antibodies and service agreements. Sale of antibodies: Revenue from sale of antibodies is recognized when the terms of a contract with a customer have been satisfied. This occurs when: • The control over the product has been transferred to the customer; and • The product is received by the customer or transfer of title to the customer occurs upon shipment. Following delivery, the customer bears the risks of obsolescence and loss in relation to the goods. Revenue is recognized based on the price specified in the contract, net of estimated sales discounts and returns. Contract revenue: Revenues from contracted services are generally recognized as the performance obligations are satisfied over time, and the related expenditures are incurred pursuant to the terms of the agreement. Contract revenue is recognized over time based on the input method, specifically the hours incurred. Revenue is recognized as the work progresses, in proportion to the amount of labor hours expended on the contract. For contracts with no enforceable right to payment when the contract is incomplete, contract revenue is recognized when the customers are satisfied with the service at the end of the contract and control of the product has been transferred to the customer. We apply the practical expedient outlined in IFRS 15.121, which allows us not to disclose information about remaining performance obligations as our contract duration is less than one year and we have the right to invoice for performance to date. The following table summarizes revenue recognized over time versus at a point in time for the years ended April 30: Years ended Timing of recognition 2024 2023 2022 Point-in-time 22,235 18,677 17,356 Over time 2,283 1,988 2,008 24,518 20,665 19,364 Unbilled revenue and deferred revenue: Amounts recognized as revenue in excess of billings are classified as unbilled revenue. Amounts received in advance of the performance of services are classified as deferred revenue. Cost of sales: Cost of sales includes materials, direct labor, and allocation of overhead including depreciation of lab equipment. Cash and Cash Equivalents Cash and cash equivalents in the statement of financial position comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value and are readily convertible to known amounts of cash. Recognition and Measurement Cash and cash equivalents are initially recognized at fair value and subsequently measured at amortized cost using the effective interest method, less any impairment losses. Due to the short-term nature of these instruments, the carrying amount is considered to be the same as their fair value. Restricted Cash Restricted cash is classified separately from cash and cash equivalents. It represents amounts that are held in trust or escrow accounts or that are otherwise restricted as to withdrawal or usage. The nature and purpose of restrictions on cash balances are disclosed in the notes to the financial statements. Restricted cash is not considered a component of cash and cash equivalents for the purpose of the statement of cash flows. Financial instruments Recognition and Classification The Company recognizes a financial asset or financial liability on the statement of financial position when it becomes party to the contractual provisions of the financial instrument. The Company classifies its financial instruments in the following categories: at fair value through profit and loss (“FVTPL”), at fair value through other comprehensive income (loss) (“FVTOCI”) or at amortized cost. The Company determines the classification of financial assets at initial recognition. The classification of debt instruments is driven by the Company’s business model for managing the financial assets and their contractual cash flow characteristics. Equity instruments that are held for trading are classified as FVTPL. For other equity instruments, on the day of acquisition the Company can make an irrevocable election (on an instrument-by-instrument basis) to designate them as at FVTOCI. Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL (such as instruments held for trading or derivatives) or if the Company has opted to measure them at FVTPL. Classification and measurement IFRS 9 Cash Amortized cost Amounts receivable Amortized cost Investment FVTPL Accounts payable and accrued liabilities Amortized cost Convertible Debentures Amortized cost Deferred acquisition payments Amortized cost Measurement Financial assets and liabilities at FVTPL: Financial assets and liabilities carried at FVTPL are initially recorded at fair value and transaction costs are expensed in profit or loss. Realized and unrealized gains and losses arising from changes in the fair value of the financial assets and liabilities held at FVTPL are included in profit or loss in the period in which they arise. Where management has opted to recognize a financial liability at FVTPL, any changes associated with the Company’s own credit risk will be recognized in other comprehensive income (loss). Financial assets at FVTOCI: Elected investments in equity instruments at FVTOCI are initially recognized at fair value plus transaction costs. Subsequently they are measured at fair value, with gains and losses recognized in other comprehensive income (loss). Financial assets and liabilities at amortized cost: Financial assets and liabilities at amortized cost are initially recognized at fair value plus or minus transaction costs, respectively, and subsequently carried at amortized cost less any impairment. Impairment of financial assets at amortized cost: The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost. At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve month expected credit losses. Irrespective of the preceding policy, the Company always measures the loss allowance of trade receivables at an amount equal to the lifetime expected credit losses. The Company shall recognize in profit or loss, as an impairment gain or loss, the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized. Derecognition Financial assets: The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity. Gains and losses on derecognition are generally recognized in profit or loss. However, gains and losses on derecognition of financial assets classified as FVTOCI remain within accumulated other comprehensive income (loss). Financial liabilities: The Company derecognizes financial liabilities only when its obligations under the financial liabilities are discharged, cancelled or expired. Generally, the difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets, is recognized in profit or loss. Government assistance The Company periodically applies for financial assistance under available government incentive programs. Government assistance relating to capital expenditures is reflected as a reduction of the cost of such assets. Government assistance relating to research and development expenditures is recorded as a reduction of current year's expenses when the related expenditures are incurred. Government grant The Company periodically applies for financial assistance under available government incentive programs. The grant is recognized when there is reasonable assurance that the Company will comply with the conditions attached to them and the grants will be received. All funds received as part of the grant or subsidies are reflected in grant and subsidy income. Inventory Inventory consists of supplies, parts and antibodies and is valued at the lower of weighted average cost and net realizable value. Costs include acquisition, freight and other directly attributable costs. Equipment and leasehold improvements Equipment and leasehold improvements are stated at cost, less accumulated depreciation and impairment losses. Depreciation is provided using the straight-line method over the following terms: Asset Basis Term Lab equipment Straight line 5 years Furniture and equipment Straight line 5 years Computer hardware Straight line 2 years Computer software Straight line 1 year Building Straight line Remaining term of the property lease Automobile Straight line Remaining term of the automobile lease Leasehold improvements Straight line Shorter of useful life and remaining term of the lease plus the first renewal option The Company evaluates equipment and leasehold improvements for indications of impairment at the end of each reporting period. Impairment losses are immediately recognized in profit and loss. Intangible assets Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses. Internally generated intangibles, excluding capitalized development costs, are not capitalized and the related expenditure is reflected in profit or loss in the period in which the expenditure is incurred. The useful lives of intangible assets are assessed as either finite or indefinite. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortization period or method, as appropriate, and are treated as changes in accounting estimates. Amortization for intangible assets with finite lives is provided over the following terms: Asset Basis Term Internally generated development costs Straight line 5 years Intellectual property Straight line 10 - 15 years Proprietary processes Straight line 5 years Certifications Straight line 1 year Customer list Straight line 2 years Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually, either individually or at the cash-generating unit ("CGU") level. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in profit or loss when the asset is derecognized. During the year ended April 30, 2024, the Company recorded an impairment of intangible assets charge of $ 3.9 million related to the BioStrand CGU. See Note 9 for more information. Goodwill Goodwill represents the excess of the purchase price in a business combination over the fair value of net tangible and intangible assets acquired. Goodwill is not subject to amortization and an impairment test is performed annually or as events occur that could indicate impairment. Goodwill is reported at cost less any impairment. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (“CGU”). To test for impairment, goodwill is allocated to each of the Company’s CGUs, groups of CGUs, or an operating segment expected to benefit from the acquisition. Goodwill is tested by combining the carrying amounts of equipment and leasehold improvements, intangible assets and goodwill and comparing this to the recoverable amount. Fair value less costs of disposal is price to be received in an orderly transaction between market participants. Value in use is assessed using the present value of the expected future cash flows. Any excess of the carrying amount over the recoverable amount is recorded as impairment. Impairment charges, which are not tax affected, are recognized in profit or loss and are not reversed. During the year ended April 30, 2023, the Company recorded an impairment charge of $ 2.5 million related to the BioStrand CGU. During the year ended April 30, 2024, the Company recorded an impairment of goodwill charge of $ 11.2 million related to the BioStrand CGU. See Note 9 for more information. Impairment of long-lived assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by comparison of their carrying amount to the recoverable amount. The recoverable amount is the higher of the fair value less costs of disposal or the value in use. Value in use is determined by the present value of the future cash flows from the asset. If the recoverable amount is less than the carrying amount, then there is impairment. Where an impairment loss exists, the portion of the carrying amount exceeding the recoverable amount is recorded as an expense immediately. Assets that have been impaired in prior periods are tested for possible reversal of impairment whenever events or changes in circumstance indicate that the impairment has reversed. If the impairment has reversed, the carrying amount of the asset is increased to its recoverable amount but not beyond the carrying amount that would have been determined had no impairment loss been recognized for the asset in prior periods. The reversal is recognized in profit or loss immediately. During the year ended April 30, 2024, the Company recorded an impairment of intangible assets charge of $ 3.9 million and an impairment of goodwill charge of $ 11.2 million related to the BioStrand CGU. The impairment losses were determined based on fair value less costs of disposal, considering discount rates, growth rates, and other relevant factors. See Note 8 and Note 9 for more information. Income taxes Income taxes are recognized in the statement of comprehensive loss, except where they relate to items recognized directly in equity, in which case the related taxes are recognized in equity. Deferred tax assets and liabilities are recognized based on the difference between the tax and accounting values of assets and liabilities and are calculated using enacted or substantively enacted tax rates for the periods in which the differences are expected to reverse. The effect of tax rate changes is recognized in profit or loss or equity, as applicable, in the period of substantive enactment. Current taxes receivable or payable are estimated on taxable income for the current year at the statutory tax rates enacted or substantively enacted. Deferred tax assets are recognized only to the extent that it is probable that future taxable profits of the relevant entity or group of entities, in a particular jurisdiction, will be available against which the assets can be utilized. As an exception, deferred tax assets and liabilities are not recognized if the temporary differences arise from the initial recognition of goodwill or an asset or liability in a transaction (other than in a business combination) that affects neither accounting profit nor taxable profit. Investment tax credits (“ITCs”) are accounted for as a reduction in the cost of the expense when there is reasonable assurance that such credits will be realized. These ITCs are used to reduce current income taxes payable. Leases At inception of a contract, the Company assesses whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The liabilities for leases of right-of-use assets are recognized at the lease commencement date at the present value of the lease payments that are not paid at that date. The lease payments are discounted using the Company’s incremental borrowing rate. At the commencement date, a right-of-use asset is measured at cost, which is comprised of the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any decommissioning and restoration costs, less any lease incentives received. Each lease payment is allocated between repayment of the lease principal and interest. Interest on the lease liability in each period during the lease term is allocated to produce a constant periodic rate of interest on the remaining balance of the lease liability. Except where the costs are included in the carrying amount of another asset, the Company recognizes in profit or loss (a) the interest on a lease liability and (b) variable lease payments not included in the measurement of a lease liability in the period in which the event or condition that triggers those payments occurs. The Company subsequently measures the right-of-use asset at cost less any accumulated depreciation and any accumulated impairment losses; and adjusted for any remeasurement of the lease liability. Right-of-use assets are depreciated over the shorter of the asset’s useful life or the lease term, except where the lease contains a bargain purchase option a right-of-use asset is depreciated over the asset’s useful life. Research and development Research and development cost is charged to the income statement in the period in which it is incurred. Property, plant and equipment used for research and development is capitalized and depreciated in accordance with the equipment and leasehold improvements policy. Share capital Equity instruments are contracts that give a residual interest in the net assets of the Company. The Company's common shares are classified as equity instruments. Proceeds from unit placements are allocated between common shares and warrants issued based on the residual value method, with the common shares being valued first. Share issuance costs Costs directly identifiable with the raising of share capital financing are charged against share capital. Share issuance costs incurred in advance of share subscriptions are recorded as deferred assets. Share issuance costs related to uncompleted share subscriptions are charged to operations. Share-based payments Where equity-settled share options are awarded to employees, the fair value of the options at the date of grant is charged to profit or loss over the vesting period. Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options, measured immediately before and after the modification, is also charged to profit or loss over the remaining vesting period. Where equity instruments are granted to non-employees, they are recorded at the fair value of the goods or services received in profit or loss, unless they are related to the issuance of shares. Amounts related to the issuance of shares are recorded as a reduction of share capital. When the value of goods or services received in exchange for the share-based payment cannot be reliably estimated, the fair value is measured by use of a valuation model. The expected life used in the model is adjusted, based on management’s best estimate, for the effects of non-transferability, exercise restrictions, and behavioral considerations. All equity-settled share-based payments are reflected in contributed surplus, until exercised. Upon exercise, shares are issued from treasury and the amount reflected in contributed surplus is credited to share capital, adjusted for any consideration paid. Where a grant of options is cancelled or settled during the vesting period, excluding forfeitures when vesting conditions are not satisfied, the Company immediately accounts for the cancellation as an acceleration of vesting and recognizes the amount that otherwise would have been recognized for services received over the remainder of the vesting period. Any payment made to the employee on the cancellation is accounted for as the repurchase of an equity interest except to the extent the payment exceeds the fair value of the equity instrument granted, measured at the repurchase date. Any such excess is recognized as an expense. Earnings (loss) per share Basic earnings (loss) per share is calculated by dividing the net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Dilutive earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. In periods where a net loss is incurred, potentially dilutive common shares are excluded from the loss per share calculation as the effect would be anti-dilutive and basic and diluted loss per common share is the same. In a profit year, under the treasury stock method, the weighted average number of common shares outstanding used for the calculation of diluted earnings per share assumes that the proceeds to be received on the exercise of dilutive stock options and warrants are used to repurchase common shares at the average price during the year.

Adoption of New Accounting Stan

Adoption of New Accounting Standards	12 Months Ended
	Apr. 30, 2024
Disclosure of initial application of standards or interpretations [abstract]
Adoption of New Accounting Standards	4. ADOPTION OF NEW ACCOUNTING STANDARDS Standards not yet adopted Classification of Liabilities as Current or Non-Current (Amendments to IAS 1) The amendments to IAS 1 provide a more general approach to the classification of liabilities based on the contractual arrangements in place at the reporting date. These amendments are effective for reporting periods beginning on or after January 1, 2024, which is our fiscal year ending April 30, 2025. We will adopt these amendments in our first fiscal quarter ending July 31, 2024.

Critical Accounting Estimates A

Critical Accounting Estimates And Judgements	12 Months Ended
	Apr. 30, 2024
Critical Accounting Estimates And Judgments [Abstract]
CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS	5. CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS The preparation of the consolidated financial statements in conformity with IFRS required estimates and judgments that affect the amounts reported in the financial statements. Actual results could differ from these estimates and judgments. Estimates are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the year in which the estimate is revised. Judgments Business combinations Acquisitions of a business are accounted for as a business combination if the assets acquired and liabilities assumed constitute a business in accordance with IFRS 3. Judgment is required to determine if the transaction meets the definition of a business combination. During the year ended April 30, 2022, the Company acquired all the issued and outstanding shares of Idea Family BV, BioStrand BV, BioKey BV, and BioClue BV (collectively “BioStrand”), as detailed in Note 6. Management concluded that BioStrand met the definition of a business and accounted for the transaction as a business combination. The acquisition of BioStrand includes potential future earn-out payments dependent on the future profitability of the business. Judgment was required to determine whether the payments constitute an exchange for the business or are transactions separate from the business combination. The potential future earn-out payments to the selling shareholders of BioStrand will be accounted for separate from the business combination (see Note 18). Impairments For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows called a cash-generating unit (“CGU"). Management applies judgment to determine CGUs. Each asset or CGU is evaluated every reporting period to determine whether there are any indicators of impairment. If any such indicators exist, which is often judgment based, a formal estimate of recoverable amount is performed and an impairment charge is recognized to the extent that the carrying amount exceeds the recoverable amount. The Company performs a goodwill impairment test annually and when circumstances indicate that the carrying value may not be recoverable. For the purposes of impairment testing, goodwill acquired through business combinations has been allocated to three different CGUs, the Company’s Oss and Utrecht locations at IPA Europe, and BioStrand. The goodwill allocated to Oss and Utrecht was $ 3.1 million and $ 4.6 million, respectively, as of April 30, 2024. The goodwill allocated to Oss, Utrecht and BioStrand was $ 3.1 million, $ 4.7 million, and $ 11.4 million, respectively, as of April 30, 2023. The goodwill allocated to BioStrand was fully impaired as of April 30, 2024 (see Note 9). Estimates Business combinations At acquisition date, the identifiable assets acquired and liabilities assumed in a business combination are recognized at their fair value. Goodwill is measured as the excess of the consideration transferred over the net of the acquisition-date fair values of the identifiable assets acquired and liabilities assumed. Estimates are required to determine the fair value of assets acquired and liabilities assumed, and estimated fair values may vary from prices that would be achieved in an arm’s length transaction at the acquisition date (see Note 6). Impairment of long-lived assets The recoverable amount of an asset or CGU of assets is measured at the higher of fair value less costs of disposal or value in use. These determinations and their individual assumptions require that management make a decision based on the best available information at each reporting period. The estimates and assumptions are subject to risk and uncertainty; hence, there is the possibility that changes in circumstances will alter these projections, which may impact the recoverable amount of the assets. In such circumstances, some or all of the carrying value of the assets may be further impaired or the impairment charge reversed with the impact recorded in profit or loss. The recoverable amount of each CGU was based on value in use, determined by discounting the future cash flows to be generated from the continuing use of the CGU. The cash flows were projected over a five-year period for the Company's Utrecht and Oss locations, and a seven-year period for BioStrand. The projections are based on past experience and actual operating results. The Company performed its annual goodwill impairment test for April 2024 and identified impairment of the BioStrand CGU. The values assigned to the key assumptions represented management’s assessment of future trends in the industry and were based on historical data from both internal and external sources. See Note 9 for details on the weighted average cost of capital used in the assessments of the three CGUs. Useful life of intangible assets Intangible assets are amortized based on estimated useful life less their estimated residual value. Significant assumptions are involved in the determination of useful life and residual values and no assurance can be given that the actual useful lives and residual values will not differ significantly from current assumptions. Actual useful life and residual values may vary depending on a number of factors including internal technical evaluation, attributes of the assets and experience with similar assets. Changes to these estimates may affect the carrying value of assets, net income (loss) and comprehensive income (loss) in future periods (see Note 8). Share-based payments Where equity-settled share options are awarded to employees, the fair value of the options at the date of grant is charged to profit and loss over the vesting period. The Company makes assumptions to determine the estimated forfeiture rate of the share options, and these estimates are reviewed at the end of each reporting period. Changes to these estimates may affect contributed surplus and net income (loss) (see Note 12).

Acquisition of BioStrand

Acquisition of BioStrand	12 Months Ended
	Apr. 30, 2024
BioStrand B.V.
Disclosure Of Business Combinations [Line Items]
ACQUISITION OF BIOSTRAND	6. ACQUISITION OF BIOSTRAND On April 13, 2022, the Company acquired all the issued and outstanding shares of BioStrand B.V., BioKey B.V., BioClue B.V. and Idea Family B.V. (collectively “BioStrand”) on terms as follows: € 2.7 million (CAD $ 3.7 million) was paid in cash on closing; 4,077,774 common shares of the Company were issued on closing; Deferred cash payment of € 0.5 million (CAD $ 0.7 million) to be paid 90 days subsequent to closing; and Deferred cash payment of € 0.5 million (CAD $ 0.6 million) to be paid over 3 years on the anniversary of the closing date. BioStrand focuses on technology in the field of bioinformatics and biotechnology related to the identification of characteristic biological sequences in proteins, RNA and DNA, and their different information layers, the development of a knowledge base containing these characteristic biological sequences and information layers, and the use of this database to process biological sequences and compare processed biological sequences. The acquisition provides the Company with advanced omics capabilities to enhance its antibody discovery processes and offer multi-omics data analysis to its clients. The transaction was accounted for as a business combination, as the operations of BioStrand meet the definition of a business. As the transaction was accounted for as a business combination, legal and consulting costs of $ 0.7 million and $ 0.1 million, respectively, were expensed during the year ended April 30, 2022. The goodwill resulting from the allocation of the purchase price to the total fair value of net assets will represent the sales growth potential and assembled workforce of BioStrand. During the three months ended July 31, 2022, the Company recorded the right-of-use assets and lease liabilities in connection with building and vehicle leases at BioStrand. During the three months ended October 31, 2022, the Company adjusted goodwill upon the finalization of the deferred cash payment paid 90 days subsequent to closing. Both adjustments occurred during the measurement period and were applied retrospectively. The Company has allocated the purchase price as follows: (in thousands) $ Cash 4,985 Common shares of the Company 29,126 Fair value of consideration 34,111 Cash 36 Amounts receivable 80 Unbilled revenue 8 Equipment and right-of-use assets 247 Intellectual property (not deductible for tax purposes) 28,459 Proprietary processes (not deductible for tax purposes) 391 Goodwill (not deductible for tax purposes) 12,658 Accounts payable and accrued liabilities assumed ( 342 ) Deferred revenue 9 Leases ( 223 ) Deferred income tax liability ( 7,212 ) 34,111 The intellectual property assets are primarily comprised of acquired technology assets that are expected to have a useful life of 15 years . The fair value of the 4,077,774 common shares issued ($ 29.1 million) was determined based on the Canadian dollar equivalent of the consideration required of € 21.3 million pursuant to the share purchase agreement using the closing stock price at` the date of the acquisition. The common shares are subject to an escrow agreement and will be released to the vendors on the following schedule: 15 % one year after closing, 20 % two years after closing, and 65 % three years after closing. The operating results for BioStrand have been recognized in the consolidated statement of comprehensive loss beginning on April 13, 2022, the effective date of control. During the year ended April 30, 2022, the Company recorded a net loss of $ 0.2 million related to BioStrand. The deferred cash payments of € 1.0 million was fair valued on the date of acquisition using a discounted cash flow model. The changes in the value of the subsequent payments during the years ended April 30, 2024, 2023 and 2022 are as follows: (in thousands) $ Balance, April 30, 2022 1,305 Foreign exchange 45 Accretion 27 Working capital adjustment ( 68 ) Deferred acquisition payment ( 592 ) Balance, April 30, 2023 717 Foreign exchange ( 12 ) Accretion 19 Disposal ( 294 ) Deferred acquisition payment ( 146 ) Balance, April 30, 2024 284 Less: Current portion ( 284 ) Non-current portion — The share purchase agreement related to the acquisition of BioStrand includes contingent earnout payments (see Note 18).

Property and Equipment

Property and Equipment	12 Months Ended
	Apr. 30, 2024
Disclosure of detailed information about property, plant and equipment [abstract]
PROPERTY AND EQUIPMENT	7. PROPERTY AND EQUIPMENT The table below includes both property and equipment and right-of-use assets. (in thousands) Computer Furniture & Computer Building Automobile Leasehold Lab WIP - Leasehold Total Cost: Balance, April 30, 2022 136 35 47 2,586 239 353 5,672 138 9,206 Additions 138 — — 7,593 — 101 1,064 28 8,924 Completion of work-in-process — — — — — 166 — ( 166 ) — Disposals ( 3 ) — — ( 1,290 ) ( 95 ) — ( 700 ) — ( 2,088 ) Foreign exchange 17 18 3 196 23 6 437 — 700 Balance, April 30, 2023 288 53 50 9,085 167 626 6,473 — 16,742 Additions 56 — — 7,826 1 27 1,316 31 9,257 Disposals ( 111 ) ( 31 ) ( 49 ) ( 1,634 ) — ( 344 ) ( 2,554 ) — ( 4,723 ) Foreign exchange ( 4 ) ( 1 ) ( 1 ) ( 133 ) ( 3 ) ( 2 ) ( 92 ) — ( 236 ) Balance, April 30, 2024 229 21 — 15,144 165 307 5,143 31 21,040 Accumulated Depreciation: Balance, April 30, 2022 70 29 47 1,736 46 348 3,371 — 5,647 Depreciation 84 3 — 1,109 58 40 977 — 2,271 Disposals ( 3 ) — — ( 1,274 ) ( 57 ) — ( 507 ) — ( 1,841 ) Foreign exchange 6 1 3 181 10 — 72 — 273 Balance, April 30, 2023 157 33 50 1,752 57 388 3,913 — 6,350 Depreciation 101 4 — 1,723 56 58 849 — 2,791 Disposals ( 110 ) ( 31 ) ( 49 ) ( 1,606 ) — ( 344 ) ( 2,554 ) — ( 4,694 ) Foreign exchange ( 2 ) — ( 1 ) ( 38 ) ( 1 ) — ( 61 ) — ( 103 ) Balance, April 30, 2024 146 6 — 1,831 112 102 2,147 — 4,344 Net Book Value: April 30, 2023 131 20 — 7,333 110 238 2,560 — 10,392 April 30, 2024 83 15 — 13,313 53 205 2,996 31 16,696

Intangible Assets

Intangible Assets	12 Months Ended
	Apr. 30, 2024
Disclosure of detailed information about intangible assets [abstract]
INTANGIBLE ASSETS	8. INTANGIBLE ASSETS Changes in the value of the intangible assets during the years ended April 30, 2024, 2023 and 2022 are as follows: (in thousands) Internally Generated Intellectual Proprietary Certifications Customer List Total Cost: Balance, April 30, 2022 33 31,914 7,359 126 180 39,612 Foreign exchange — 3,229 744 13 18 4,004 Balance, April 30, 2023 33 35,143 8,103 139 198 43,616 Impairments and disposals — ( 3,830 ) ( 40 ) — ( 193 ) ( 4,063 ) Foreign exchange — ( 595 ) ( 136 ) ( 3 ) ( 5 ) ( 739 ) Balance, April 30, 2024 33 30,718 7,927 136 — 38,814 Accumulated Amortization: Balance, April 30, 2022 8 1,693 5,491 — 30 7,222 Amortization 7 2,710 1,477 128 92 4,414 Foreign exchange ( 1 ) 372 665 9 10 1,055 Balance, April 30, 2023 14 4,775 7,633 137 132 12,691 Amortization 19 2,666 216 2 65 2,968 Disposals — — — — ( 193 ) ( 193 ) Foreign exchange — ( 75 ) ( 127 ) ( 3 ) ( 4 ) ( 209 ) Balance, April 30, 2024 33 7,366 7,722 136 — 15,257 Net Book Value: April 30, 2023 19 30,368 470 2 66 30,925 April 30, 2024 — 23,352 205 — — 23,557

Goodwill

Goodwill	12 Months Ended
	Apr. 30, 2024
Disclosure of detailed information about intangible assets [abstract]
Goodwill	9. GOODWILL The goodwill was acquired as a result of the acquisitions of U-Protein, IPA Europe and, BioStrand. The changes in the value of goodwill during the year ended April 30, 2024, 2023 and 2022 are as follows: (in thousands) $ Balance, April 30, 2022 19,635 Foreign exchange 1,996 Asset impairment ( 2,460 ) Balance, April 30, 2023 19,171 Foreign exchange ( 323 ) Asset impairment ( 11,161 ) Balance, April 30, 2024 7,687 Impairment testing For annual impairment testing, goodwill is allocated to the following cash-generating units ("CGU"): (in thousands) April 30, April 30, Oss 3,056 3,109 Utrecht 4,631 4,710 BioStrand — 11,352 7,687 19,171 The recoverable amount of each CGU was based on value-in-use calculations and determined using a five-year forecast for Utrecht and Oss and a seven-year forecast for BioStrand, followed by a terminal growth rate determined by management. The present value of the forecasted cash flows of each CGU is determined by applying a discount rate reflecting a current market assessment of the time value of money and risks specific to the CGU. The recoverable amount, growth rate assumptions and discount rates for each CGU as of April 30, 2024, 2023 and 2022 are as follows: Recoverable amount Terminal growth rates Discount rates (in thousands) 2024 2023 2024 2023 2024 2023 Oss 5,965 6,723 2.5 % 2.5 % 22.0 % 21.6 % Utrecht 12,737 11,405 2.5 % 2.5 % 19.0 % 18.6 % BioStrand 14,611 31,546 2.5 % 2.5 % 45.0 % 33.1 % The terminal growth rates consider the average GDP growth rate of the Netherlands and Belgium. The discount rates reflect management’s assessment of market and specific risk of the CGU. Both the Oss and Utrecht CGUs operate in the same region and are included in the same operating segment of the Company. The cash flow forecasts include a key management assumption that future profit margins will remain stable and is based on previous performance of the CGU. The assumption for future profit margins is based on management’s review of the prior three years of performance of the CGU. During the year ended April 30, 2023, the Company recorded an impairment loss of $ 2.5 million for the BioStrand CGU. The loss was recorded as a reduction in goodwill. The primary factor for the impairment included a rise in the discount rate as compared to the prior year, along with a delay in expected cash flows in the forecast. The increased discount rate relates to increases in the forecast risk for the BioStrand CGU, increased economic risk, and increased global interest rates as compared to the prior year. During the year ended April 30, 2024, the Company recorded an impairment loss of $ 11.2 million on impairment of goodwill and $ 3.9 million on impairment of intangible assets for the BioStrand CGU. The loss was recorded as a reduction in goodwill and the intangible assets. The primary factor for the impairment included a rise in the discount rate as compared to the prior year, along with a delay in expected cash flows in the forecast. The increased discount rate relates to increases in the forecast risk for the BioStrand CGU, increased economic risk, and increased global interest rates as compared to the prior year.

Convertible Debentures

Convertible Debentures	12 Months Ended
	Apr. 30, 2024
Convertible Debentures [Abstract]
CONVERTIBLE DEBENTURES	10. CONVERTIBLE DEBENTURES On May 15, 2020, the Company closed a non-brokered private placement financing by issuing 10 % convertible debentures (“New Debentures”) for total proceeds of $ 2.59 million. On May 27, 2020, the Company issued an additional $ 0.04 million of the 10 % New Debentures. In total, the Company issued $ 2.6 million of the New Debentures. The New Debentures are unsecured, bear interest at a rate of 10 % per year and payable at maturity. The maturity date is May 15, 2022 for $ 2.59 million of the New Debentures and May 22, 2022 for $ 0.04 million of the New Debentures. The principal amount of the New Debentures may be convertible, at the option of the holder, into units of the Company at a conversion price of $ 4.25 per share. The Company may force convert the principal amount of the New Debentures at $4.25 per share if the average closing price is equal to or greater than $7.50 for 20 trading days. The fair value of the New Debentures at the time of issue was calculated as the discounted cash flows assuming a 15 % effective interest rate. The fair value of the equity component was determined at the time of issue as the difference between the face value and the fair value of the New Debentures. On initial recognition, the Company bifurcated $ 2.4 million to the carrying value of the New Debentures and $ 0.2 million to the equity component. Under the financing, the Company paid finder’s cash commissions totaling $ 0.08 million and incurred legal and filing fees of $ 0.03 million. The transaction costs were allocated pro-rata based on the carrying values of the New Debentures and the equity component, with $ 0.1 million allocated to the New Debentures and $ 0.01 million allocated to the equity component. The changes in the value of the New Debentures during the years ended April 30, 2024, 2023 and 2022 are as follows: (in thousands) Liability Equity Balance, April 30, 2022 1,312 103 Accretion expense 3 — Conversion to shares ( 1,315 ) ( 103 ) Balance, April 30, 2024 and 2023 — —

Leases

Leases	12 Months Ended
	Apr. 30, 2024
Presentation of leases for lessee [abstract]
LEASES	11. LEASES The Company has leases for lab and office space, automobiles and one item of lab equipment. Each lease is reflected in the consolidated statement of financial position as a right-of-use asset and a lease liability. The Company classifies right-of-use assets in a consistent manner to its property and equipment. The following is a schedule of the Company’s future minimum lease payments related to the equipment and automobiles under finance lease and the office lease obligation: (in thousands) $ 2025 2,444 2026 2,411 2027 2,408 2028 2,402 2029 2,104 More than 5 years 5,763 Total minimum lease payments 17,532 Less: imputed interest ( 3,851 ) Total present value of minimum lease payments 13,681 Less: Current portion ( 1,563 ) Non-current portion 12,118 Total cash outflow for leases during the year ended April 30, 2024 was $ 1.3 million (2023 - $ 1.3 and 2022 - $ 1.0 million). The nature of the Company’s leases by type of right-of-use asset as of April 30, 2024 is as follows: Right-of-use asset type No. of Range Average No. of No. of No. of No. of Lab and office facilities 3 6 - 10 years 8 years 2 — 2 2 Automobiles 6 0.5 - 3 years 1 years — — 6 6 Right-of-use assets The Company reviews long-lived assets with finite useful lives for impairment whenever circumstances indicate that the carrying amount of the asset may not be recoverable. During the year ended April 30, 2022, a significant change in the planned use of a right-of-use asset related to leased office space indicated possible impairment of the asset. Due to the nature of the leased space, the Company determined the recoverable amount to be nominal, and recorded an impairment charge of $ 0.2 million in general & administrative expense, the full carrying value of the asset. During the year ended April 30, 2023, the Company recorded a right-of-use asset of $ 7.4 million upon commencement of a new lease at the Utrecht, the Netherlands location. The lease includes an initial term of five years , and a renewal option for an additional five years . The Company has determined that it is reasonably certain to exercise the renewal option. During the year ended April 30, 2024, the Company recorded a right-of-use asset of $ 3.7 million upon commencement of a new lease at the Oss, the Netherlands location. The lease includes an initial term of five years , and a renewal option. The Company has determined that it is reasonably certain to exercise the renewal option. During the year ended April 30, 2024, the Company recorded a right-of-use asset of $ 3.5 million upon commencement of a new lease at the Victoria, the Canadian location. The lease includes an initial term of ten years . The changes in the value of right-of-use assets during the years ended April 30, 2024, 2023 and 2022 are as follows: (in thousands) Building Automobile Lab Equipment Total Cost: Balance, April 30, 2022 2,586 239 651 3,476 Additions 7,593 — — 7,593 Disposals ( 1,290 ) ( 95 ) ( 687 ) ( 2,072 ) Foreign exchange 196 23 36 255 Balance, April 30, 2023 9,085 167 — 9,252 Additions 7,826 1 — 7,827 Disposals ( 1,634 ) — — ( 1,634 ) Foreign exchange ( 133 ) ( 3 ) — ( 136 ) Balance, April 30, 2024 15,144 165 — 15,309 Accumulated Depreciation: Balance, April 30, 2022 1,736 46 460 2,242 Depreciation 1,109 58 198 1,365 Disposals ( 1,274 ) ( 57 ) ( 507 ) ( 1,838 ) Foreign exchange 181 10 ( 151 ) 40 Balance, April 30, 2023 1,752 57 — 1,809 Depreciation 1,723 56 — 1,779 Disposals ( 1,606 ) — — ( 1,606 ) Foreign exchange ( 38 ) ( 1 ) — ( 39 ) Balance, April 30, 2024 1,831 112 — 1,943 Net Book Value: April 30, 2023 7,333 110 — 7,443 April 30, 2024 13,313 53 — 13,366 Lease payments not recognized as a liability The Company has elected not to recognize a lease liability for leases with an expected term of 12 months or less. Additionally, certain variable lease payments are not permitted to be recognized as lease liabilities and are recognized in profit and loss as incurred. The expense relating to payments not included in the measurement of the lease liability during the years ended April 30, 2024, 2023 and 2022 are as follows: (in thousands) 2024 2023 Leases of low value assets 7 40 Variable lease payments 467 215 474 255

Share Capital

Share Capital	12 Months Ended
	Apr. 30, 2024
Disclosure of classes of share capital [abstract]
SHARE CAPITAL	12. SHARE CAPITAL a) Authorized: Unlimited common shares without par value. b) Share capital transactions: 2022 Transactions On May 3, 2021, the Company issued 41,488 common shares pursuant to the final deferred payment for the acquisition of IPA Europe. The common shares were valued at $ 0.5 million. On April 13, 2022, the Company issued 4,077,774 common shares pursuant to the acquisition of BioStrand (Note 6). The common shares were valued at $ 29.1 million. During the year ended April 30, 2022, the Company issued 188,000 common shares pursuant to the exercise of stock options for total gross proceeds of $ 0.6 million. A value of $ 0.4 million was transferred from contributed surplus to share capital as a result. The weighted average share price at the dates the stock options were exercised was $ 7.95 . During the year ended April 30, 2022, the Company issued 925,076 common shares pursuant to the exercise of warrants and finder’s warrants for total gross proceeds of $ 3.2 million. A value of $ 0.3 million was transferred from contributed surplus to share capital as a result. During the year ended April 30, 2022, the Company issued 75,292 common shares with a value of $ 0.3 million pursuant to the conversion of $ 0.3 million principal balance of convertible debentures. 2023 Transactions During the year ended April 30, 2023, the Company issued 263,537 common shares pursuant to the exercise of stock options for total gross proceeds of $ 0.7 million. A value of $ 0.8 million was transferred from contributed surplus to share capital as a result. The weighted average share price at the dates the stock options were exercised was U.S.$ 4.50 . During the year ended April 30, 2023, the Company issued 309,877 common shares with a value of $ 1.3 million pursuant to the conversion of $ 1.3 million principal balance of convertible debentures. 2024 Transactions During the year ended April 30, 2024, the Company issued 1,265,000 common shares in an underwritten public offering, including 165,000 common shares issued pursuant to the full exercise by the underwriter of its over-allotment option. The public offering price for each common share, before the underwriter's discount and commissions, was U.S.$ 1.00 . During the year ended April 30, 2024, the Company established an at-the-market equity offering facility ("ATM Facility") with Clear Street LLC, replacing its previous ATM Facility with Jefferies LLC, which was terminated on February 1, 2024. An Open Market Sales Agreement ("ATM Agreement") was entered into with Clear Street LLC, as sole sales agent ("Agent") on February 23, 2024. The Company is entitled, at its discretion and from time-to-time during the term of the ATM Agreement, to sell, through the Agent common shares of the Company. On February 23, 2024, in connection with the ATM facility, the Company filed a prospectus supplement permitting the sales of common shares having an aggregate gross sales price of up to US$ 60.0 million. Sales of the common shares will be made in transactions that are deemed to be "at-the-market distributions" as defined in Rule 415(a)(4) of the United Securities Act of 1933, as amended, including, without limitation, sales made directly on Nasdaq or any other existing trading market for the common shares in the United States. Common shares will only be sold on the facilities of an exchange or market outside Canada to purchasers who the Company has no reason to believe are resident in Canada and, in all others cases, to purchasers who are not located or resident in Canada. The Company will determine, at its sole discretion, the date, minimum price and maximum number of common shares to be sold under the ATM Facility. The common shares will be distributed from time to time in negotiated transactions, at market prices prevailing at the time of sale, at prices relating to such prevailing market prices, and/or in any other manner permitted by applicable law. As such, the prices may vary between purchasers over time. The Company is not required to sell any common shares at any time during the term of the ATM Facility. In fiscal 2024, 629,240 common shares were sold under the ATM with proceeds net of commissions of $1.8 million. From May 1, 2024 through July 26, 2024, 357,760 common shares were sold under the ATM with proceeds net of commissions of $0.5 million. c) Options The following table summarizes stock option awards during the years ended April 30, 2024, 2023 and 2022, including the fair value determined using the Black-Scholes option pricing model: Grant date Stock Exercisable price/option Awarded to Share price Dividend yield Expected volatility Risk-free rate Expected life Fair value January 2, 2022 (1) 28,250 6.89 Directors 6.89 0 % 77 % 1.18 % 4.0 years $ 0.1 million January 7, 2022 (2) 225,000 7.94 Officers and employees 7.94 0 % 77 % 1.42 % 5.0 years $ 1.1 million January 7, 2022 (2) 113,000 7.94 Employees 7.94 0 % 77 % 1.42 % 4.7 years $ 0.5 million January 13, 2022 (4) 15,000 8.30 Officer 8.30 0 % 77 % 1.43 % 1.0 years $ 0.04 million January 13, 2022 (2) 24,000 8.30 Employees 8.30 0 % 77 % 1.43 % 4.7 years $ 0.1 million March 11, 2022 (5) 25,000 6.35 Consultant 4.67 0 % 76 % 1.77 % 2.0 years $ 0.03 million May 15, 2022 (2) 80,000 5.79 Employees 3.79 0 % 77 % 2.73 % 5.0 years $ 0.3 million February 19, 2023 (1) 29,060 4.10 (7) Directors 4.10 (7) 0 % 77 % 3.57 % 4.0 years $ 0.1 million February 19, 2023 (2) 609,452 4.10 (7) Officers and employees 4.10 (7) 0 % 77 % 3.57 % 5.0 years $ 2.2 million January 19, 2024 (6) 240,000 1.48 (7) Directors 1.48 (7) 0 % 77 % 3.64 % 5.0 years $ 0.4 million January 4, 2023 (6) 8,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 12 thousand January 23, 2023 (6) 8,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 12 thousand March 1, 2023 (6) 8,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 12 thousand March 15, 2023 (6) 4,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 6 thousand April 2, 2023 (6) 4,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 6 thousand May 8, 2023 (6) 4,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 6 thousand May 23, 2023 (6) 4,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 6 thousand June 11, 2023 (6) 8,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 12 thousand August 8, 2023 (6) 4,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 6 thousand November 13, 2023 (6) 8,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 12 thousand January 1, 2024 (6) 12,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 18 thousand February 1, 2024 (6) 4,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 6 thousand February 19, 2024 (6) 12,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 18 thousand February 20, 2024 (6) 4,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 6 thousand (1) Vesting conditions are as follows: one-quarter 3 months after grant date; one-quarter 6 months after grant date; one-quarter 9 months after grant date; and one-quarter 12 months after grant date. (2) Vesting conditions are as follows: one-third 6 months after grant date; one-third 12 months after grant date; and one-third 18 months after grant date. (3) Vesting conditions are as follows: one-third one year after grant date; one-third two years after grand date; and one-third three years after grant date. (4) Vesting conditions are as follows: one-third 2 months after grant date; one-third 4 months after grant date; and one-third 6 months after grant date. (5) Vesting conditions are as follows: one-half 3 months after grant date; one-half 6 months after grant date. (6) Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date . (7) Priced in U.S.$ Expected volatility of options granted is based on the historical volatility of the company from January 1, 2019 to the option grant date. During the year ended April 30, 2024, the Company has recorded $ 1.5 million (2023 - $ 1.9 and 2022 - $ 3.1 million) of share-based payments expense. The changes in the stock options for the years ended April 30, 2024, 2023 and 2022 are as follows: Number of Weighted Weighted Balance, April 30, 2022 (outstanding) 1,624,150 8.29 2.88 Granted 718,512 5.58 — Exercised ( 318,725 ) 3.27 — Expired ( 115,174 ) 9.35 — Forfeited ( 24,335 ) 9.45 — Balance, April 30, 2023 (outstanding) 1,884,428 8.03 3.27 Granted 332,000 2.02 — Expired ( 577,335 ) 7.15 — Forfeited ( 117,726 ) 4.15 — Balance, April 30, 2024 (outstanding) 1,521,367 7.17 3.47 Unvested ( 460,595 ) 3.26 5.25 Exercisable, April 30, 2024 1,060,772 8.87 2.70 Details of the options outstanding as at April 30, 2024 are as follows: Expiry Date Exercise Remaining Options Unvested Exercisable September 1, 2025 8.50 1.34 220,000 — 220,000 January 6, 2026 20.30 1.69 158,000 — 158,000 May 9, 2026 (1) 6.89 1.68 5,650 - 5,650 January 2, 2026 7.94 2.69 235,000 — 235,000 January 7, 2027 8.30 2.71 16,000 - 16,000 May 15, 2027 5.79 3.04 72,000 - 72,000 February 19, 2027 (2) 5.61 2.81 7,265 - 7,265 February 19, 2028 (2) 5.61 3.81 475,452 158,484 316,968 January 19, 2034 (3) 2.03 4.73 240,000 217,778 22,222 January 4, 2033 (4) 2.01 8.69 8,000 5,667 2,333 January 23, 2033 (4) 2.01 8.74 8,000 5,667 2,333 March 1, 2033 (4) 2.01 8.84 8,000 6,000 2,000 March 15, 2033 (4) 2.01 8.88 4,000 3,000 1,000 April 2, 2033 (4) 2.01 8.93 4,000 4,000 — May 8, 2033 (4) 2.01 9.03 4,000 4,000 — May 23, 2033 (4) 2.01 9.07 4,000 4,000 — June 11, 2033 (4) 2.01 9.12 8,000 8,000 — August 8, 2033 (4) 2.01 9.28 4,000 4,000 — November 13, 2033 (4) 2.01 9.55 8,000 8,000 — January 1, 2034 (4) 2.01 9.68 12,000 12,000 — February 1, 2034 (4) 2.01 9.76 4,000 4,000 — February 19, 2034 (4) 2.01 9.81 12,000 12,000 — February 20, 2034 (4) 2.01 9.82 4,000 4,000 — 7.17 3.47 1,521,367 460,595 1,060,772 (1) Exercise price of U.S.$ 7.72 . The figure in the table above is translated at the April 30, 2024 rate. (2) Exercise price of U.S.$ 4.10 . The figure in the table above is translated at the April 30, 2024 rate. (3) Exercise price of U.S.$ 1.48 . The figure in the table above is translated at the April 30, 2024 rate. (4) Exercise price of U.S.$ 1.47 . The figure in the table above is translated at the April 30, 2024 rate. d) Warrants The changes in the warrants for the years ended April 30, 2024, 2023 and 2022 are as follows: Number of Weighted Weighted Balance, April 30, 2021 878,300 3.50 0.90 Exercised ( 878,300 ) 3.50 — Balance, April 30, 2024, 2023 and 2022 — — — d) Finder’s Warrants The changes in the finder’s warrants for the years ended April 30, 2024, 2023 and 2022 are as follows: Number of Weighted average Weighted average life Balance, April 30, 2022 130,111 21.59 3.77 Exercised — — — Balance, April 30, 2023 130,111 22.77 2.77 Issued 56,650 1.37 4.61 Exercised — — — Balance, April 30, 2024 186,761 16.44 2.62 Details of the finder’s warrants outstanding as at April 30, 2024 are as follows: Expiry Date Exercise price Remaining life Warrants February 3, 2026 (1) 23.00 1.76 130,111 December 8, 2028 (2) 1.37 4.61 56,650 (1) Exercise price of U.S.$ 16.81 . The figure in the table above is translated at the April 30, 2024 rate. (2) Exercise price of U.S.$ 1.00 . The figure in the table above is translated at the April 30, 2024 rate.

Employee Remuneration

Employee Remuneration	12 Months Ended
	Apr. 30, 2024
Disclosure of employee benefits expenses [abstract]
EMPLOYEE REMUNERATION	13. EMPLOYEE REMUNERATION Expenses recognized for employee benefits for the years ended April 30, 2024, 2023 and 2022 are detailed below: (in thousands) 2024 2023 2022 Wages, salaries 10,733 10,433 8,600 Employee benefits 938 926 798 Payroll taxes 774 939 714 Severance 60 194 8 Share-based payments 1,535 1,943 3,083 14,040 14,435 13,203

Related Party Transactions

Related Party Transactions	12 Months Ended
	Apr. 30, 2024
Related party transactions [abstract]
RELATED PARTY TRANSACTIONS	14. RELATED PARTY TRANSACTIONS Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company. Key management consists of Dr. Jennifer Bath, President and CEO; Kristin Taylor, CFO; Brad McConn, former CFO; Dr. Stefan Lang, former Chief Business Officer; Dr. Ilse Roodink, Chief Scientific Officer; Lisa Helbling, former Director and Chief Financial Officer, Dr. Barry Duplantis, former Vice President of Client Relations; Dr. Yasmina Abdiche, former Chief Scientific Officer; and Directors of the Company. During the years ended April 30, 2024, 2023 and 2022, the compensation for key management is as follows: (in thousands) 2024 2023 2022 Salaries and other short-term benefits 2,454 2,632 2,531 Severance (included in salaries) 60 183 8 Share-based payments expense 928 986 1,388 Director compensation (included in salaries) 343 335 355 3,785 4,136 4,282 At April 30, 2024, included in accounts payable and accrued liabilities is $ 0.3 million (April 30, 2023 - $ 0.9 million and 2022 - $ 0.4 million) due to related parties. The amounts payable are non-interest bearing and unsecured.

Capital Management

Capital Management	12 Months Ended
	Apr. 30, 2024
Capital Management [Abstract]
CAPITAL MANAGEMENT	15. CAPITAL MANAGEMENT The Company’s objectives when managing capital are to ensure sufficient liquidity for operations and adequate funding for growth and capital expenditures while maintaining an efficient balance between debt and equity. The capital structure of the Company consists of shareholders’ equity of $ 31.4 million. The Company makes adjustments to its capital structure upon approval from its Board of Directors, in light of economic conditions and the Company’s working capital requirements. There were no changes in the Company’s approach to capital management during the year. The Company is not subject to any externally imposed capital requirements.

Financial Instruments

Financial Instruments	12 Months Ended
	Apr. 30, 2024
Disclosure of detailed information about financial instruments [abstract]
FINANCIAL INSTRUMENTS	16. FINANCIAL INSTRUMENTS The Company’s financial instruments include cash, amounts receivable, restricted cash, investment, accounts payable and accrued liabilities, debentures, loans payable, leases and deferred acquisition payments. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy establishes three levels to classify the inputs to valuation techniques used to measure fair value, by reference to the reliability of the inputs used to estimate the fair values. Level 1 – applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 – applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 – applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The fair value of investment is determined based on “Level 2” inputs as its value under the equity method was the best approximation of its fair value. As at April 30, 2024, the Company believes the carrying values of cash, amounts receivable, restricted cash, accounts payable and accrued liabilities, leases and deferred acquisition payments approximate their fair values because of their nature and relatively short maturity dates or durations. Concentration of risk: Concentrations of credit risk Credit risk relates to cash, restricted cash and amounts receivable and arises from the possibility that counterparty to an instrument may fail to perform. At April 30, 2024, all of the Company’s cash was held with tier one banks. Details of amounts receivable and allowance for credit losses as of April 30, 2024, 2023 and 2022 are as follows: (in thousands) 2024 2023 2022 Amounts receivable 3,819 3,280 2,539 Allowance for credit losses ( 29 ) ( 33 ) ( 36 ) Amounts receivable, net 3,790 3,247 2,503 Currency risk The Company operates in the US and Europe which gives rise to exposure to market risks from changes in foreign currency values. Most significantly, the Company is exposed to potential currency fluctuations between US and Canadian dollars, which was translated at 1.3686 at April 30, 2024, and the Euro and Canadian dollar, which was translated at 1.4680 at April 30, 2024. Fluctuations in the exchange rate could impact profitability. At April 30, 2024, the Company is exposed to currency risk through the following assets and liabilities denominated in US dollars and Euros: Euros US Dollars (in thousands) (€) (U.S.$) Cash 784 551 Amounts receivable 1,847 568 2,631 1,119 Accounts payable and accrued liabilities ( 1,344 ) ( 1,258 ) Deferred acquisition payments ( 193 ) — Leases ( 882 ) — ( 2,419 ) ( 1,258 ) Net 212 ( 139 ) Liquidity risk The Company’s approach to managing its obligations is to maintain sufficient resources to meet its obligations when due without undue risk to the Company. The Company monitors its cash requirements on an ongoing basis to ensure that there are sufficient resources for operations as well as to fund anticipated leasing, capital and development expenditures. In addition, the Company manages its cash to meet its obligations and to fund general and administrative costs. Contractual cash flow requirements as of April 30, 2024 were as follows: < 1 1 - 2 2 - 5 >5 Total (in thousands) $ $ $ $ $ Accounts payable and accrued liabilities 4,372 — — — 4,372 Leases 2,444 2,411 6,914 5,763 17,532 Total 6,816 2,411 6,914 5,763 21,904

Inventories

Inventories	12 Months Ended
	Apr. 30, 2024
Inventories [Abstract]
INVENTORIES	17. INVENTORIES Inventories as of April 30, 2024, 2023 and 2022 consist of the following: (in thousands) 2024 2023 Supplies and parts 1,734 1,344 Antibodies 190 206 Work in process 215 510 2,139 2,060 For the years ended April 30, 2024, 2023 and 2022, inventory write-offs amounted to nil , $ 0.3 million, and nil , respectively. These write-offs were primarily due to obsolescence and changes in market conditions affecting the net realizable value of the inventory.

Commitments

Commitments	12 Months Ended
	Apr. 30, 2024
Commitments [Abstract]
COMMITMENTS	18. COMMITMENTS The share purchase agreement related to the acquisition of BioStrand includes contingent earnout payments based on 20 % of the EBITDA of BioStrand, as defined in the share purchase agreement, over a 7-year period, which shall not exceed in total € 12.0 million. The Company has determined these payments relate to post-acquisition services because they are contingent on the employment of two key employees and will be expensed in the period earned. As of April 30, 2024, the Company's unpaid commitment related to the BioStrand earnout is € 12.0 million.

Grant and Subsidy Income

Grant and Subsidy Income	12 Months Ended
	Apr. 30, 2024
Grant And Subsidy Income [Abstract]
GRANT AND SUBSIDY INCOME	19. GRANT AND SUBSIDY INCOME During May 2022, the Company received a € 0.5 million round of grant funding from VLAIO (Flanders Innovation & Entrepreneurship), the research fund of the Flemish regional government in Belgium. The Company received the first disbursement of € 0.2 million during the three months ended July 31, 2022. During the year ended April 30, 2024, the Company recorded € 0.2 million in grant income related to this funding compared to the € 0.2 million recorded in year ended April 30, 2023.

Segmented Information and Econo

Segmented Information and Economic Dependence	12 Months Ended
	Apr. 30, 2024
Disclosure of operating segments [abstract]
SEGMENTED INFORMATION AND ECONOMIC DEPENDENCE	20. SEGMENTED INFORMATION AND ECONOMIC DEPENDENCE At April 30, 2024, April 30, 2023 and 2022, the Company has one reportable segment, being antibody production and related services. The Company’s revenues are allocated to geographic regions for the year ended April 30, 2024, 2023 and 2022 as follows: Years ended Revenue by Region 2024 2023 2022 United States of America 12,556 9,365 6,816 Europe 10,867 9,450 9,429 Canada 389 618 572 Australia 482 630 1,540 Other 224 602 1,007 24,518 20,665 19,364 The Company’s revenues are allocated according to revenue types for the year ended April 30, 2024, 2023 and 2022 as follows: Years ended Revenue Allocation 2024 2023 2022 Project revenue 22,235 18,677 17,356 Product sales revenue 2,035 1,747 1,652 Cryostorage revenue 248 241 356 24,518 20,665 19,364 As of April 30, 2024, all deferred revenue is expected to be recognized over the next twelve months. The Company’s non-current assets are allocated to geographic regions as of April 30, 2024, 2023 and 2022 as follows: Non-Current Assets 2024 2023 2022 North America - Corporate 80 89 76 North America 4,138 1,025 1,481 Belgium 22,261 40,406 41,355 Netherlands 22,022 19,501 13,265 48,501 61,021 56,177 Geographic segmentation of the Company’s net income (loss) for the year ended April 30, 2024, 2023 and 2022 is as follows: Years ended Net Income (Loss) by Region 2024 2023 2022 North America - Corporate ( 7,846 ) ( 8,422 ) ( 9,340 ) North America ( 449 ) ( 12,601 ) ( 11,424 ) Belgium ( 20,071 ) ( 7,024 ) ( 215 ) Netherlands 1,189 1,487 4,270 ( 27,177 ) ( 26,560 ) ( 16,709 ) Geographic segmentation of the interest and accretion, and amortization and depreciation for the year ended April 30, 2024, 2023 and 2022 is as follows: Years ended Interest and accretion (in thousands) 2024 2023 2022 North America - Corporate 4 39 258 North America 231 19 51 Belgium — 20 3 Netherlands 619 318 107 854 396 419 Years ended Amortization and depreciation (in thousands) 2024 2023 2022 North America - Corporate 11 14 56 North America 687 720 778 Belgium 2,422 2,543 — Netherlands 2,615 3,408 2,935 5,735 6,685 3,769

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	12 Months Ended
	Apr. 30, 2024
Statement of cash flows [abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	21. SUPPLEMENTAL CASH FLOW INFORMATION Non-cash investing and financing transactions (in thousands) April 30, April 30, April 30, Acquisition of building and equipment by lease 7,826 7,593 312 Settlement of convertible debentures — 1,315 304 Fair value of shares issued pursuant to deferred acquisition payment to IPA Europe — — 503 The following changes in liabilities arose from financing activities: Non-cash changes (in thousands) April 30, Cash Flows Acquisition Settlement Accretion Foreign April 30, Deferred acquisition payments 649 ( 146 ) — ( 294 ) 19 56 284 Leases 7,267 ( 1,339 ) 7,593 — — 160 13,681 Total 7,916 ( 1,485 ) 7,593 ( 294 ) 19 216 13,965 Non-cash changes (in thousands) April 30, Cash Flows Acquisition Settlement Accretion Foreign April 30, Deferred acquisition payments 1,237 ( 592 ) — — 27 ( 23 ) 649 Convertible debentures 1,312 — — ( 1,315 ) 3 — — Leases 1,455 ( 1,337 ) 7,593 — — ( 444 ) 7,267 Total 4,004 ( 1,929 ) 7,593 ( 1,315 ) 30 ( 467 ) 7,916 Non-cash changes (in thousands) April 30, Cash Flows Acquisition Debt forgiven Accretion Foreign April 30, Deferred acquisition payments 498 — 1,248 ( 503 ) — ( 6 ) 1,237 Convertible debentures 1,531 — — ( 304 ) 85 — 1,312 Leases 1,926 ( 962 ) 533 — — ( 42 ) 1,455 Total 3,955 ( 962 ) 1,781 ( 807 ) 85 ( 48 ) 4,004

Income Taxes

Income Taxes	12 Months Ended
	Apr. 30, 2024
Disclosure Of Income Taxes [Abstract]
INCOME TAXES	22. INCOME TAX Income tax expense differs from the amount that would be computed by applying the federal and provincial statutory tax rates of (2024 – 27 %, 2023 – 27 %, and 2022 – 27 %) to the earnings before income taxes. The reasons for the differences and related tax effects are as follows: 2024 2023 2022 $ $ $ Earnings (loss) before income taxes ( 28,703 ) ( 27,752 ) ( 15,848 ) Income taxes (recovery) on earnings before income taxes, at above basic rate ( 7,750 ) ( 7,493 ) ( 3,627 ) Increase (decrease) in taxes resulting from: Nondeductible expenses 1 8 322 Estimated SR&ED ITC ( 166 ) ( 198 ) — Effects of tax rate change and foreign exchange — 209 12 Deferred income tax asset recognized — — ( 138 ) Tax rate difference by jurisdiction 588 948 ( 359 ) Tax benefits not recognized 3,072 4,885 4,651 Impairment loss 2,790 602 — Prior year tax assessments and adjustments ( 183 ) ( 420 ) — Other 122 267 — Income taxes (recovery) ( 1,526 ) ( 1,192 ) 861 2024 2023 2022 $ $ $ Current income taxes 177 ( 242 ) 1,390 Deferred income taxes (recovery) ( 1,703 ) ( 950 ) ( 529 ) Income taxes (recovery) ( 1,526 ) ( 1,192 ) 861 Temporary differences give rise to the following deferred income tax assets and liabilities: 2024 2023 2022 $ $ $ Other tax pools 31 ( 20 ) Capital assets net of lease liabilities 16 ( 61 ) 8 Inventory and intangible assets ( 5,841 ) ( 7,631 ) ( 8,093 ) Recognized deferred income tax liabilities ( 5,825 ) ( 7,661 ) ( 8,105 ) 2024 2023 2022 $ $ $ Non-capital losses carried forward (expire from 2027 to 2040 ) 13,424 9,930 10,514 Other tax pools — — 1,373 Capital losses carried forward 295 295 194 Capital assets net of lease liabilities — 20 13 Financing costs 402 746 979 Less: unrecognized deferred income tax asset ( 14,121 ) ( 10,991 ) ( 13,073 ) Unrecognized deferred income tax liabilities — — —

Subsequent Events

Subsequent Events	12 Months Ended
	Apr. 30, 2024
Disclosure of non-adjusting events after reporting period [abstract]
SUBSEQUENT EVENTS	23. SU BSEQUENT EVENTS On July 16, 2024 A II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP (“Yorkville”), under which the Company agreed to sell and issue to Yorkville U.S.$ 3.0 million aggregate principal amount of convertible debentures (the “Convertible Debentures”) in two tranches and at a purchase price of 95 % of the aggregate principal amount. The Convertible Debentures are convertible into common shares of the Company (the “Common Shares”). The sale and issue of the first tranche consists of U.S.$ 2.0 million principal amount of Convertible Debentures and was completed on July 16, 2024 (the “First Closing”). The sale and issue of the second tranche consists of U.S.$ 1.0 million principal amount of Convertible Debentures and is expected to close on or about the date the initial Registration Statement (as defined in the Registration Rights Agreement (as defined below)) has first been declared effective by the United States Securities and Exchange Commission (the “SEC”). Each Convertible Debenture will be an unsecured obligation of the Company and will be wholly and unconditionally guaranteed by certain of the Company’s subsidiaries. The Convertible Debentures will incur interest at a rate of 8.0 % per annum. The outstanding principal amount of and accrued and unpaid interest, if any, on, the Convertible Debentures must be paid by the Company in cash when the same becomes due and payable under the terms of the Convertible Debentures at their stated maturity, upon their redemption or otherwise. The Convertible Debentures are redeemable at any time provided that the volume-weighted average price (“VWAP”) for the Common Shares is less than U.S.$ 1.16 , at a redemption price equal to the principal amount, plus accrued and unpaid interest on the principal amount to be redeemed, plus a 10 % premium. If at any time on and after November 1, 2024, the daily VWAP for the Common Shares is less than U.S.$ 0.20 for five Trading Days during a period of seven consecutive Trading Days or a default with respect to the Registration Statement has occurred, the Company shall be required to make monthly installments payments on the Convertible Debentures in an amount equal to U.S.$ 300,000 principal amount, plus accrued and unpaid interest on the outstanding principal amount, plus a 10 % premium. Subject to certain limitations contained within the Securities Purchase Agreement and the Convertible Debentures, holders of the Convertible Debentures will be entitled to convert the principal amount of, and accrued and unpaid interest, if any, on each Convertible Debenture, in whole or in part, from time to time, into a number of Common Shares at a Conversion Price equal to the lower of (i) U.S.$ 1.16 per Common Share, or (ii) 95% of the lowest daily VWAP for the Common Shares during the 10 consecutive trading days immediately preceding the conversion date or other date of determination (the “Market Price”), but which Market Price shall not be lower than U.S.$ 0.20 . The Conversion Price is subject to anti-dilution adjustments pursuant to the terms and conditions of the Securities Purchase Agreement and the Convertible Debentures. During any consecutive 30-day period, the holders of the Convertible Debentures may not, without the prior written consent of the Company, convert more than U.S.$ 300,000 in principal amount of Convertible Notes during any 30-day period if the Conversion Price is less than U.S.$ 1.16 , provided, however, that the foregoing limitation shall not apply during the occurrence and during the continuance of an event of default under the Convertible Debentures. In connection with the offering, the Company and Yorkville entered into a customary Registration Rights Agreement (the “Registration Rights Agreement”) pursuant to which the Company has agreed to provide certain registration rights to Yorkville under the U.S. Securities Act of 1933, as amended. The Company intends to use the net proceeds from the proposed offering for research and development; capital expenditures; working capital; and general corporate purposes. During the year ended April 30, 2024, the Company established an at-the-market equity offering facility ("ATM Facility") with Clear Street LLC, replacing its previous ATM Facility with Jefferies LLC, which was terminated on February 1, 2024. From May 1, 2024 through July 26, 2024, 357,760 common shares were sold under the ATM with proceeds net of commissions of $0.5 million.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Apr. 30, 2024
Disclosure Of Significant Accounting Policies [Abstract]
Business combinations	Business combinations Acquisitions of businesses are accounted for using the acquisition model. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition-date fair values of the assets transferred by the Company, liabilities incurred by the Company to the former owners of the acquiree and the equity interests issued by the Company in exchange for control of the acquiree. Acquisition-related costs are recognized in profit or loss as incurred. At the acquisition date, the identifiable assets acquired, and the liabilities assumed are recognized at their fair value at the acquisition date. Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the acquisition-date amounts of the identifiable assets acquired and the liabilities assumed. If, after reassessment, the net of the acquisition-date amounts of the identifiable assets acquired and liabilities assumed exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer's previously held interest in the acquiree (if any), the excess is recognized immediately in profit or loss as a bargain purchase gain. When the consideration transferred by the Company in a business combination includes assets or liabilities resulting from a contingent consideration arrangement, the contingent consideration is measured at its acquisition-date fair value and included as part of the consideration transferred in a business combination. Changes in the fair value of the contingent consideration that qualify as measurement period adjustments are adjusted retrospectively, with corresponding adjustments against goodwill. Measurement period adjustments are adjustments that arise from additional information obtained during the ‘measurement period’ (which cannot exceed one year from the acquisition date) about facts and circumstances that existed at the acquisition date.
Revenue recognition	Revenue recognition The Company recognizes revenue from sale of antibodies and service agreements. Sale of antibodies: Revenue from sale of antibodies is recognized when the terms of a contract with a customer have been satisfied. This occurs when: • The control over the product has been transferred to the customer; and • The product is received by the customer or transfer of title to the customer occurs upon shipment. Following delivery, the customer bears the risks of obsolescence and loss in relation to the goods. Revenue is recognized based on the price specified in the contract, net of estimated sales discounts and returns. Contract revenue: Revenues from contracted services are generally recognized as the performance obligations are satisfied over time, and the related expenditures are incurred pursuant to the terms of the agreement. Contract revenue is recognized over time based on the input method, specifically the hours incurred. Revenue is recognized as the work progresses, in proportion to the amount of labor hours expended on the contract. For contracts with no enforceable right to payment when the contract is incomplete, contract revenue is recognized when the customers are satisfied with the service at the end of the contract and control of the product has been transferred to the customer. We apply the practical expedient outlined in IFRS 15.121, which allows us not to disclose information about remaining performance obligations as our contract duration is less than one year and we have the right to invoice for performance to date. The following table summarizes revenue recognized over time versus at a point in time for the years ended April 30: Years ended Timing of recognition 2024 2023 2022 Point-in-time 22,235 18,677 17,356 Over time 2,283 1,988 2,008 24,518 20,665 19,364 Unbilled revenue and deferred revenue: Amounts recognized as revenue in excess of billings are classified as unbilled revenue. Amounts received in advance of the performance of services are classified as deferred revenue. Cost of sales: Cost of sales includes materials, direct labor, and allocation of overhead including depreciation of lab equipment.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents in the statement of financial position comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value and are readily convertible to known amounts of cash. Recognition and Measurement Cash and cash equivalents are initially recognized at fair value and subsequently measured at amortized cost using the effective interest method, less any impairment losses. Due to the short-term nature of these instruments, the carrying amount is considered to be the same as their fair value. Restricted Cash Restricted cash is classified separately from cash and cash equivalents. It represents amounts that are held in trust or escrow accounts or that are otherwise restricted as to withdrawal or usage. The nature and purpose of restrictions on cash balances are disclosed in the notes to the financial statements. Restricted cash is not considered a component of cash and cash equivalents for the purpose of the statement of cash flows.
Financial instruments	Financial instruments Recognition and Classification The Company recognizes a financial asset or financial liability on the statement of financial position when it becomes party to the contractual provisions of the financial instrument. The Company classifies its financial instruments in the following categories: at fair value through profit and loss (“FVTPL”), at fair value through other comprehensive income (loss) (“FVTOCI”) or at amortized cost. The Company determines the classification of financial assets at initial recognition. The classification of debt instruments is driven by the Company’s business model for managing the financial assets and their contractual cash flow characteristics. Equity instruments that are held for trading are classified as FVTPL. For other equity instruments, on the day of acquisition the Company can make an irrevocable election (on an instrument-by-instrument basis) to designate them as at FVTOCI. Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL (such as instruments held for trading or derivatives) or if the Company has opted to measure them at FVTPL. Classification and measurement IFRS 9 Cash Amortized cost Amounts receivable Amortized cost Investment FVTPL Accounts payable and accrued liabilities Amortized cost Convertible Debentures Amortized cost Deferred acquisition payments Amortized cost Measurement Financial assets and liabilities at FVTPL: Financial assets and liabilities carried at FVTPL are initially recorded at fair value and transaction costs are expensed in profit or loss. Realized and unrealized gains and losses arising from changes in the fair value of the financial assets and liabilities held at FVTPL are included in profit or loss in the period in which they arise. Where management has opted to recognize a financial liability at FVTPL, any changes associated with the Company’s own credit risk will be recognized in other comprehensive income (loss). Financial assets at FVTOCI: Elected investments in equity instruments at FVTOCI are initially recognized at fair value plus transaction costs. Subsequently they are measured at fair value, with gains and losses recognized in other comprehensive income (loss). Financial assets and liabilities at amortized cost: Financial assets and liabilities at amortized cost are initially recognized at fair value plus or minus transaction costs, respectively, and subsequently carried at amortized cost less any impairment. Impairment of financial assets at amortized cost: The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost. At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve month expected credit losses. Irrespective of the preceding policy, the Company always measures the loss allowance of trade receivables at an amount equal to the lifetime expected credit losses. The Company shall recognize in profit or loss, as an impairment gain or loss, the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized. Derecognition Financial assets: The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity. Gains and losses on derecognition are generally recognized in profit or loss. However, gains and losses on derecognition of financial assets classified as FVTOCI remain within accumulated other comprehensive income (loss). Financial liabilities: The Company derecognizes financial liabilities only when its obligations under the financial liabilities are discharged, cancelled or expired. Generally, the difference between the carrying amount of the financial liability derecognized and the consideration paid and payable, including any non-cash assets, is recognized in profit or loss.
Government assistance	Government assistance The Company periodically applies for financial assistance under available government incentive programs. Government assistance relating to capital expenditures is reflected as a reduction of the cost of such assets. Government assistance relating to research and development expenditures is recorded as a reduction of current year's expenses when the related expenditures are incurred.
Government grant	Government grant The Company periodically applies for financial assistance under available government incentive programs. The grant is recognized when there is reasonable assurance that the Company will comply with the conditions attached to them and the grants will be received. All funds received as part of the grant or subsidies are reflected in grant and subsidy income.
Inventory	Inventory Inventory consists of supplies, parts and antibodies and is valued at the lower of weighted average cost and net realizable value. Costs include acquisition, freight and other directly attributable costs.
Equipment and leasehold improvements	Equipment and leasehold improvements Equipment and leasehold improvements are stated at cost, less accumulated depreciation and impairment losses. Depreciation is provided using the straight-line method over the following terms: Asset Basis Term Lab equipment Straight line 5 years Furniture and equipment Straight line 5 years Computer hardware Straight line 2 years Computer software Straight line 1 year Building Straight line Remaining term of the property lease Automobile Straight line Remaining term of the automobile lease Leasehold improvements Straight line Shorter of useful life and remaining term of the lease plus the first renewal option The Company evaluates equipment and leasehold improvements for indications of impairment at the end of each reporting period. Impairment losses are immediately recognized in profit and loss.
Intangible assets	Intangible assets Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses. Internally generated intangibles, excluding capitalized development costs, are not capitalized and the related expenditure is reflected in profit or loss in the period in which the expenditure is incurred. The useful lives of intangible assets are assessed as either finite or indefinite. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortization period or method, as appropriate, and are treated as changes in accounting estimates. Amortization for intangible assets with finite lives is provided over the following terms: Asset Basis Term Internally generated development costs Straight line 5 years Intellectual property Straight line 10 - 15 years Proprietary processes Straight line 5 years Certifications Straight line 1 year Customer list Straight line 2 years Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually, either individually or at the cash-generating unit ("CGU") level. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in profit or loss when the asset is derecognized. During the year ended April 30, 2024, the Company recorded an impairment of intangible assets charge of $ 3.9 million related to the BioStrand CGU. See Note 9 for more information.
Goodwill	Goodwill Goodwill represents the excess of the purchase price in a business combination over the fair value of net tangible and intangible assets acquired. Goodwill is not subject to amortization and an impairment test is performed annually or as events occur that could indicate impairment. Goodwill is reported at cost less any impairment. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (“CGU”). To test for impairment, goodwill is allocated to each of the Company’s CGUs, groups of CGUs, or an operating segment expected to benefit from the acquisition. Goodwill is tested by combining the carrying amounts of equipment and leasehold improvements, intangible assets and goodwill and comparing this to the recoverable amount. Fair value less costs of disposal is price to be received in an orderly transaction between market participants. Value in use is assessed using the present value of the expected future cash flows. Any excess of the carrying amount over the recoverable amount is recorded as impairment. Impairment charges, which are not tax affected, are recognized in profit or loss and are not reversed. During the year ended April 30, 2023, the Company recorded an impairment charge of $ 2.5 million related to the BioStrand CGU. During the year ended April 30, 2024, the Company recorded an impairment of goodwill charge of $ 11.2 million related to the BioStrand CGU. See Note 9 for more information.
Impairment of long-lived assets	Impairment of long-lived assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by comparison of their carrying amount to the recoverable amount. The recoverable amount is the higher of the fair value less costs of disposal or the value in use. Value in use is determined by the present value of the future cash flows from the asset. If the recoverable amount is less than the carrying amount, then there is impairment. Where an impairment loss exists, the portion of the carrying amount exceeding the recoverable amount is recorded as an expense immediately. Assets that have been impaired in prior periods are tested for possible reversal of impairment whenever events or changes in circumstance indicate that the impairment has reversed. If the impairment has reversed, the carrying amount of the asset is increased to its recoverable amount but not beyond the carrying amount that would have been determined had no impairment loss been recognized for the asset in prior periods. The reversal is recognized in profit or loss immediately. During the year ended April 30, 2024, the Company recorded an impairment of intangible assets charge of $ 3.9 million and an impairment of goodwill charge of $ 11.2 million related to the BioStrand CGU. The impairment losses were determined based on fair value less costs of disposal, considering discount rates, growth rates, and other relevant factors. See Note 8 and Note 9 for more information.
Income taxes	Income taxes Income taxes are recognized in the statement of comprehensive loss, except where they relate to items recognized directly in equity, in which case the related taxes are recognized in equity. Deferred tax assets and liabilities are recognized based on the difference between the tax and accounting values of assets and liabilities and are calculated using enacted or substantively enacted tax rates for the periods in which the differences are expected to reverse. The effect of tax rate changes is recognized in profit or loss or equity, as applicable, in the period of substantive enactment. Current taxes receivable or payable are estimated on taxable income for the current year at the statutory tax rates enacted or substantively enacted. Deferred tax assets are recognized only to the extent that it is probable that future taxable profits of the relevant entity or group of entities, in a particular jurisdiction, will be available against which the assets can be utilized. As an exception, deferred tax assets and liabilities are not recognized if the temporary differences arise from the initial recognition of goodwill or an asset or liability in a transaction (other than in a business combination) that affects neither accounting profit nor taxable profit. Investment tax credits (“ITCs”) are accounted for as a reduction in the cost of the expense when there is reasonable assurance that such credits will be realized. These ITCs are used to reduce current income taxes payable.
Leases	Leases At inception of a contract, the Company assesses whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The liabilities for leases of right-of-use assets are recognized at the lease commencement date at the present value of the lease payments that are not paid at that date. The lease payments are discounted using the Company’s incremental borrowing rate. At the commencement date, a right-of-use asset is measured at cost, which is comprised of the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any decommissioning and restoration costs, less any lease incentives received. Each lease payment is allocated between repayment of the lease principal and interest. Interest on the lease liability in each period during the lease term is allocated to produce a constant periodic rate of interest on the remaining balance of the lease liability. Except where the costs are included in the carrying amount of another asset, the Company recognizes in profit or loss (a) the interest on a lease liability and (b) variable lease payments not included in the measurement of a lease liability in the period in which the event or condition that triggers those payments occurs. The Company subsequently measures the right-of-use asset at cost less any accumulated depreciation and any accumulated impairment losses; and adjusted for any remeasurement of the lease liability. Right-of-use assets are depreciated over the shorter of the asset’s useful life or the lease term, except where the lease contains a bargain purchase option a right-of-use asset is depreciated over the asset’s useful life.
Research and development	Research and development Research and development cost is charged to the income statement in the period in which it is incurred. Property, plant and equipment used for research and development is capitalized and depreciated in accordance with the equipment and leasehold improvements policy.
Share capital	Share capital Equity instruments are contracts that give a residual interest in the net assets of the Company. The Company's common shares are classified as equity instruments. Proceeds from unit placements are allocated between common shares and warrants issued based on the residual value method, with the common shares being valued first.
Share issuance costs	Share issuance costs Costs directly identifiable with the raising of share capital financing are charged against share capital. Share issuance costs incurred in advance of share subscriptions are recorded as deferred assets. Share issuance costs related to uncompleted share subscriptions are charged to operations.
Share-based payments	Share-based payments Where equity-settled share options are awarded to employees, the fair value of the options at the date of grant is charged to profit or loss over the vesting period. Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options, measured immediately before and after the modification, is also charged to profit or loss over the remaining vesting period. Where equity instruments are granted to non-employees, they are recorded at the fair value of the goods or services received in profit or loss, unless they are related to the issuance of shares. Amounts related to the issuance of shares are recorded as a reduction of share capital. When the value of goods or services received in exchange for the share-based payment cannot be reliably estimated, the fair value is measured by use of a valuation model. The expected life used in the model is adjusted, based on management’s best estimate, for the effects of non-transferability, exercise restrictions, and behavioral considerations. All equity-settled share-based payments are reflected in contributed surplus, until exercised. Upon exercise, shares are issued from treasury and the amount reflected in contributed surplus is credited to share capital, adjusted for any consideration paid. Where a grant of options is cancelled or settled during the vesting period, excluding forfeitures when vesting conditions are not satisfied, the Company immediately accounts for the cancellation as an acceleration of vesting and recognizes the amount that otherwise would have been recognized for services received over the remainder of the vesting period. Any payment made to the employee on the cancellation is accounted for as the repurchase of an equity interest except to the extent the payment exceeds the fair value of the equity instrument granted, measured at the repurchase date. Any such excess is recognized as an expense.
Earnings (loss) per share	Earnings (loss) per share Basic earnings (loss) per share is calculated by dividing the net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Dilutive earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. In periods where a net loss is incurred, potentially dilutive common shares are excluded from the loss per share calculation as the effect would be anti-dilutive and basic and diluted loss per common share is the same. In a profit year, under the treasury stock method, the weighted average number of common shares outstanding used for the calculation of diluted earnings per share assumes that the proceeds to be received on the exercise of dilutive stock options and warrants are used to repurchase common shares at the average price during the year.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	12 Months Ended
	Apr. 30, 2024
Investments accounted for using equity method [abstract]
Summary of Subsidiaries which are Wholly Owned and Subject to Control	These consolidated financial statements include the financial statements of the Company and the following subsidiaries which are wholly owned and subject to control by the Company: Name of Subsidiary % Equity Country of Functional Currency ImmunoPrecise Antibodies (Canada) Ltd. 100 % Canada Canadian dollar ImmunoPrecise Antibodies (USA) Ltd. ("IPA USA") 100 % USA US dollar ImmunoPrecise Antibodies (N.D.) Ltd. 100 % USA US dollar ImmunoPrecise Antibodies (MA) LLC 100 % USA US dollar Talem Therapeutics LLC ("Talem") 100 % USA US dollar ImmunoPrecise Netherlands B.V. 100 % Netherlands Euro ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe") 100 % Netherlands Euro BioStrand B.V. 100 % Belgium Euro Idea Family B.V. 100 % Belgium Euro BioKey B.V. 100 % Belgium Euro BioClue B.V. 100 % Belgium Euro ImmunoPrecise Antibodies (Quebec), Ltd. 100 % Canada Canadian dollar 9438-9244 Quebec, Inc. 100 % Canada Canadian dollar

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Apr. 30, 2024
Disclosure Of Significant Accounting Policies [Abstract]
Summary of Revenue Recognized Over Time Versus at Point in Time	The following table summarizes revenue recognized over time versus at a point in time for the years ended April 30: Years ended Timing of recognition 2024 2023 2022 Point-in-time 22,235 18,677 17,356 Over time 2,283 1,988 2,008 24,518 20,665 19,364
Summary of Classification and Measurement of Financial Assets and Liabilities	Equity instruments that are held for trading are classified as FVTPL. For other equity instruments, on the day of acquisition the Company can make an irrevocable election (on an instrument-by-instrument basis) to designate them as at FVTOCI. Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL (such as instruments held for trading or derivatives) or if the Company has opted to measure them at FVTPL. Classification and measurement IFRS 9 Cash Amortized cost Amounts receivable Amortized cost Investment FVTPL Accounts payable and accrued liabilities Amortized cost Convertible Debentures Amortized cost Deferred acquisition payments Amortized cost
Schedule of Estimated Term of Asset	Equipment and leasehold improvements are stated at cost, less accumulated depreciation and impairment losses. Depreciation is provided using the straight-line method over the following terms: Asset Basis Term Lab equipment Straight line 5 years Furniture and equipment Straight line 5 years Computer hardware Straight line 2 years Computer software Straight line 1 year Building Straight line Remaining term of the property lease Automobile Straight line Remaining term of the automobile lease Leasehold improvements Straight line Shorter of useful life and remaining term of the lease plus the first renewal option
Summary of Amortization of Intangible Assets with Finite Lives	Amortization for intangible assets with finite lives is provided over the following terms: Asset Basis Term Internally generated development costs Straight line 5 years Intellectual property Straight line 10 - 15 years Proprietary processes Straight line 5 years Certifications Straight line 1 year Customer list Straight line 2 years

Acquisition of Biostrand (Table

Acquisition of Biostrand (Tables) - BioStrand B.V.	12 Months Ended
	Apr. 30, 2024
Disclosure of detailed information about business combination [line items]
Summary of Allocated Purchase Price	The Company has allocated the purchase price as follows: (in thousands) $ Cash 4,985 Common shares of the Company 29,126 Fair value of consideration 34,111 Cash 36 Amounts receivable 80 Unbilled revenue 8 Equipment and right-of-use assets 247 Intellectual property (not deductible for tax purposes) 28,459 Proprietary processes (not deductible for tax purposes) 391 Goodwill (not deductible for tax purposes) 12,658 Accounts payable and accrued liabilities assumed ( 342 ) Deferred revenue 9 Leases ( 223 ) Deferred income tax liability ( 7,212 ) 34,111
Summary of Changes in Value of Subsequent Payments	The changes in the value of the subsequent payments during the years ended April 30, 2024, 2023 and 2022 are as follows: (in thousands) $ Balance, April 30, 2022 1,305 Foreign exchange 45 Accretion 27 Working capital adjustment ( 68 ) Deferred acquisition payment ( 592 ) Balance, April 30, 2023 717 Foreign exchange ( 12 ) Accretion 19 Disposal ( 294 ) Deferred acquisition payment ( 146 ) Balance, April 30, 2024 284 Less: Current portion ( 284 ) Non-current portion —

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Apr. 30, 2024
Disclosure of detailed information about property, plant and equipment [abstract]
Summary of Changes in the Value of Property and Equipment	The table below includes both property and equipment and right-of-use assets. (in thousands) Computer Furniture & Computer Building Automobile Leasehold Lab WIP - Leasehold Total Cost: Balance, April 30, 2022 136 35 47 2,586 239 353 5,672 138 9,206 Additions 138 — — 7,593 — 101 1,064 28 8,924 Completion of work-in-process — — — — — 166 — ( 166 ) — Disposals ( 3 ) — — ( 1,290 ) ( 95 ) — ( 700 ) — ( 2,088 ) Foreign exchange 17 18 3 196 23 6 437 — 700 Balance, April 30, 2023 288 53 50 9,085 167 626 6,473 — 16,742 Additions 56 — — 7,826 1 27 1,316 31 9,257 Disposals ( 111 ) ( 31 ) ( 49 ) ( 1,634 ) — ( 344 ) ( 2,554 ) — ( 4,723 ) Foreign exchange ( 4 ) ( 1 ) ( 1 ) ( 133 ) ( 3 ) ( 2 ) ( 92 ) — ( 236 ) Balance, April 30, 2024 229 21 — 15,144 165 307 5,143 31 21,040 Accumulated Depreciation: Balance, April 30, 2022 70 29 47 1,736 46 348 3,371 — 5,647 Depreciation 84 3 — 1,109 58 40 977 — 2,271 Disposals ( 3 ) — — ( 1,274 ) ( 57 ) — ( 507 ) — ( 1,841 ) Foreign exchange 6 1 3 181 10 — 72 — 273 Balance, April 30, 2023 157 33 50 1,752 57 388 3,913 — 6,350 Depreciation 101 4 — 1,723 56 58 849 — 2,791 Disposals ( 110 ) ( 31 ) ( 49 ) ( 1,606 ) — ( 344 ) ( 2,554 ) — ( 4,694 ) Foreign exchange ( 2 ) — ( 1 ) ( 38 ) ( 1 ) — ( 61 ) — ( 103 ) Balance, April 30, 2024 146 6 — 1,831 112 102 2,147 — 4,344 Net Book Value: April 30, 2023 131 20 — 7,333 110 238 2,560 — 10,392 April 30, 2024 83 15 — 13,313 53 205 2,996 31 16,696

Intangibles assets (Tables)

Intangibles assets (Tables)	12 Months Ended
	Apr. 30, 2024
Disclosure of detailed information about intangible assets [abstract]
Summary of Amortization for intangible assets with finite lives is provided over the following terms	Changes in the value of the intangible assets during the years ended April 30, 2024, 2023 and 2022 are as follows: (in thousands) Internally Generated Intellectual Proprietary Certifications Customer List Total Cost: Balance, April 30, 2022 33 31,914 7,359 126 180 39,612 Foreign exchange — 3,229 744 13 18 4,004 Balance, April 30, 2023 33 35,143 8,103 139 198 43,616 Impairments and disposals — ( 3,830 ) ( 40 ) — ( 193 ) ( 4,063 ) Foreign exchange — ( 595 ) ( 136 ) ( 3 ) ( 5 ) ( 739 ) Balance, April 30, 2024 33 30,718 7,927 136 — 38,814 Accumulated Amortization: Balance, April 30, 2022 8 1,693 5,491 — 30 7,222 Amortization 7 2,710 1,477 128 92 4,414 Foreign exchange ( 1 ) 372 665 9 10 1,055 Balance, April 30, 2023 14 4,775 7,633 137 132 12,691 Amortization 19 2,666 216 2 65 2,968 Disposals — — — — ( 193 ) ( 193 ) Foreign exchange — ( 75 ) ( 127 ) ( 3 ) ( 4 ) ( 209 ) Balance, April 30, 2024 33 7,366 7,722 136 — 15,257 Net Book Value: April 30, 2023 19 30,368 470 2 66 30,925 April 30, 2024 — 23,352 205 — — 23,557

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Apr. 30, 2024
Disclosure of detailed information about intangible assets [abstract]
Schedule of reconciliation of changes in goodwill	The goodwill was acquired as a result of the acquisitions of U-Protein, IPA Europe and, BioStrand. The changes in the value of goodwill during the year ended April 30, 2024, 2023 and 2022 are as follows: (in thousands) $ Balance, April 30, 2022 19,635 Foreign exchange 1,996 Asset impairment ( 2,460 ) Balance, April 30, 2023 19,171 Foreign exchange ( 323 ) Asset impairment ( 11,161 ) Balance, April 30, 2024 7,687
Schedule of In Tabular Form Of Allocating Goodwill To Cash Generating Units	For annual impairment testing, goodwill is allocated to the following cash-generating units ("CGU"): (in thousands) April 30, April 30, Oss 3,056 3,109 Utrecht 4,631 4,710 BioStrand — 11,352 7,687 19,171
Schedule of information for cash-generating units	The recoverable amount, growth rate assumptions and discount rates for each CGU as of April 30, 2024, 2023 and 2022 are as follows: Recoverable amount Terminal growth rates Discount rates (in thousands) 2024 2023 2024 2023 2024 2023 Oss 5,965 6,723 2.5 % 2.5 % 22.0 % 21.6 % Utrecht 12,737 11,405 2.5 % 2.5 % 19.0 % 18.6 % BioStrand 14,611 31,546 2.5 % 2.5 % 45.0 % 33.1 %

Convertible Debentures (Tables)

Convertible Debentures (Tables)	12 Months Ended
	Apr. 30, 2024
Convertible Debentures [Abstract]
Summary of Changes in Value of New Debentures	The changes in the value of the New Debentures during the years ended April 30, 2024, 2023 and 2022 are as follows: (in thousands) Liability Equity Balance, April 30, 2022 1,312 103 Accretion expense 3 — Conversion to shares ( 1,315 ) ( 103 ) Balance, April 30, 2024 and 2023 — —

Leases (Tables)

Leases (Tables)	12 Months Ended
	Apr. 30, 2024
Presentation of leases for lessee [abstract]
Schedule of Future Minimum Lease Payments Related to Equipment under Finance Lease and Office Lease Obligation	The following is a schedule of the Company’s future minimum lease payments related to the equipment and automobiles under finance lease and the office lease obligation: (in thousands) $ 2025 2,444 2026 2,411 2027 2,408 2028 2,402 2029 2,104 More than 5 years 5,763 Total minimum lease payments 17,532 Less: imputed interest ( 3,851 ) Total present value of minimum lease payments 13,681 Less: Current portion ( 1,563 ) Non-current portion 12,118
Schedule of Nature of Company's Leases Type of Right-of-Use Asset	The nature of the Company’s leases by type of right-of-use asset as of April 30, 2024 is as follows: Right-of-use asset type No. of Range Average No. of No. of No. of No. of Lab and office facilities 3 6 - 10 years 8 years 2 — 2 2 Automobiles 6 0.5 - 3 years 1 years — — 6 6
Schedule of Changes in the Value of Right-of-Use Assets	The changes in the value of right-of-use assets during the years ended April 30, 2024, 2023 and 2022 are as follows: (in thousands) Building Automobile Lab Equipment Total Cost: Balance, April 30, 2022 2,586 239 651 3,476 Additions 7,593 — — 7,593 Disposals ( 1,290 ) ( 95 ) ( 687 ) ( 2,072 ) Foreign exchange 196 23 36 255 Balance, April 30, 2023 9,085 167 — 9,252 Additions 7,826 1 — 7,827 Disposals ( 1,634 ) — — ( 1,634 ) Foreign exchange ( 133 ) ( 3 ) — ( 136 ) Balance, April 30, 2024 15,144 165 — 15,309 Accumulated Depreciation: Balance, April 30, 2022 1,736 46 460 2,242 Depreciation 1,109 58 198 1,365 Disposals ( 1,274 ) ( 57 ) ( 507 ) ( 1,838 ) Foreign exchange 181 10 ( 151 ) 40 Balance, April 30, 2023 1,752 57 — 1,809 Depreciation 1,723 56 — 1,779 Disposals ( 1,606 ) — — ( 1,606 ) Foreign exchange ( 38 ) ( 1 ) — ( 39 ) Balance, April 30, 2024 1,831 112 — 1,943 Net Book Value: April 30, 2023 7,333 110 — 7,443 April 30, 2024 13,313 53 — 13,366
Schedule of Lease Payments Not Recognized Liability	The expense relating to payments not included in the measurement of the lease liability during the years ended April 30, 2024, 2023 and 2022 are as follows: (in thousands) 2024 2023 Leases of low value assets 7 40 Variable lease payments 467 215 474 255

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Apr. 30, 2024
Disclosure of classes of share capital [abstract]
Summary of Stock Option Awards	The following table summarizes stock option awards during the years ended April 30, 2024, 2023 and 2022, including the fair value determined using the Black-Scholes option pricing model: Grant date Stock Exercisable price/option Awarded to Share price Dividend yield Expected volatility Risk-free rate Expected life Fair value January 2, 2022 (1) 28,250 6.89 Directors 6.89 0 % 77 % 1.18 % 4.0 years $ 0.1 million January 7, 2022 (2) 225,000 7.94 Officers and employees 7.94 0 % 77 % 1.42 % 5.0 years $ 1.1 million January 7, 2022 (2) 113,000 7.94 Employees 7.94 0 % 77 % 1.42 % 4.7 years $ 0.5 million January 13, 2022 (4) 15,000 8.30 Officer 8.30 0 % 77 % 1.43 % 1.0 years $ 0.04 million January 13, 2022 (2) 24,000 8.30 Employees 8.30 0 % 77 % 1.43 % 4.7 years $ 0.1 million March 11, 2022 (5) 25,000 6.35 Consultant 4.67 0 % 76 % 1.77 % 2.0 years $ 0.03 million May 15, 2022 (2) 80,000 5.79 Employees 3.79 0 % 77 % 2.73 % 5.0 years $ 0.3 million February 19, 2023 (1) 29,060 4.10 (7) Directors 4.10 (7) 0 % 77 % 3.57 % 4.0 years $ 0.1 million February 19, 2023 (2) 609,452 4.10 (7) Officers and employees 4.10 (7) 0 % 77 % 3.57 % 5.0 years $ 2.2 million January 19, 2024 (6) 240,000 1.48 (7) Directors 1.48 (7) 0 % 77 % 3.64 % 5.0 years $ 0.4 million January 4, 2023 (6) 8,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 12 thousand January 23, 2023 (6) 8,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 12 thousand March 1, 2023 (6) 8,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 12 thousand March 15, 2023 (6) 4,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 6 thousand April 2, 2023 (6) 4,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 6 thousand May 8, 2023 (6) 4,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 6 thousand May 23, 2023 (6) 4,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 6 thousand June 11, 2023 (6) 8,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 12 thousand August 8, 2023 (6) 4,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 6 thousand November 13, 2023 (6) 8,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 12 thousand January 1, 2024 (6) 12,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 18 thousand February 1, 2024 (6) 4,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 6 thousand February 19, 2024 (6) 12,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 18 thousand February 20, 2024 (6) 4,000 1.47 (7) Employees 1.47 (7) 0 % 77 % 3.68 % 10 years $ 6 thousand (1) Vesting conditions are as follows: one-quarter 3 months after grant date; one-quarter 6 months after grant date; one-quarter 9 months after grant date; and one-quarter 12 months after grant date. (2) Vesting conditions are as follows: one-third 6 months after grant date; one-third 12 months after grant date; and one-third 18 months after grant date. (3) Vesting conditions are as follows: one-third one year after grant date; one-third two years after grand date; and one-third three years after grant date. (4) Vesting conditions are as follows: one-third 2 months after grant date; one-third 4 months after grant date; and one-third 6 months after grant date. (5) Vesting conditions are as follows: one-half 3 months after grant date; one-half 6 months after grant date. (6) Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date . (7) Priced in U.S.$
Summary of Changes in Stock Option	The changes in the stock options for the years ended April 30, 2024, 2023 and 2022 are as follows: Number of Weighted Weighted Balance, April 30, 2022 (outstanding) 1,624,150 8.29 2.88 Granted 718,512 5.58 — Exercised ( 318,725 ) 3.27 — Expired ( 115,174 ) 9.35 — Forfeited ( 24,335 ) 9.45 — Balance, April 30, 2023 (outstanding) 1,884,428 8.03 3.27 Granted 332,000 2.02 — Expired ( 577,335 ) 7.15 — Forfeited ( 117,726 ) 4.15 — Balance, April 30, 2024 (outstanding) 1,521,367 7.17 3.47 Unvested ( 460,595 ) 3.26 5.25 Exercisable, April 30, 2024 1,060,772 8.87 2.70
Summary of Options Outstanding	Details of the options outstanding as at April 30, 2024 are as follows: Expiry Date Exercise Remaining Options Unvested Exercisable September 1, 2025 8.50 1.34 220,000 — 220,000 January 6, 2026 20.30 1.69 158,000 — 158,000 May 9, 2026 (1) 6.89 1.68 5,650 - 5,650 January 2, 2026 7.94 2.69 235,000 — 235,000 January 7, 2027 8.30 2.71 16,000 - 16,000 May 15, 2027 5.79 3.04 72,000 - 72,000 February 19, 2027 (2) 5.61 2.81 7,265 - 7,265 February 19, 2028 (2) 5.61 3.81 475,452 158,484 316,968 January 19, 2034 (3) 2.03 4.73 240,000 217,778 22,222 January 4, 2033 (4) 2.01 8.69 8,000 5,667 2,333 January 23, 2033 (4) 2.01 8.74 8,000 5,667 2,333 March 1, 2033 (4) 2.01 8.84 8,000 6,000 2,000 March 15, 2033 (4) 2.01 8.88 4,000 3,000 1,000 April 2, 2033 (4) 2.01 8.93 4,000 4,000 — May 8, 2033 (4) 2.01 9.03 4,000 4,000 — May 23, 2033 (4) 2.01 9.07 4,000 4,000 — June 11, 2033 (4) 2.01 9.12 8,000 8,000 — August 8, 2033 (4) 2.01 9.28 4,000 4,000 — November 13, 2033 (4) 2.01 9.55 8,000 8,000 — January 1, 2034 (4) 2.01 9.68 12,000 12,000 — February 1, 2034 (4) 2.01 9.76 4,000 4,000 — February 19, 2034 (4) 2.01 9.81 12,000 12,000 — February 20, 2034 (4) 2.01 9.82 4,000 4,000 — 7.17 3.47 1,521,367 460,595 1,060,772 (1) Exercise price of U.S.$ 7.72 . The figure in the table above is translated at the April 30, 2024 rate. (2) Exercise price of U.S.$ 4.10 . The figure in the table above is translated at the April 30, 2024 rate. (3) Exercise price of U.S.$ 1.48 . The figure in the table above is translated at the April 30, 2024 rate. (4) Exercise price of U.S.$ 1.47 . The figure in the table above is translated at the April 30, 2024 rate.
Summary of Changes in Warrants	The changes in the warrants for the years ended April 30, 2024, 2023 and 2022 are as follows: Number of Weighted Weighted Balance, April 30, 2021 878,300 3.50 0.90 Exercised ( 878,300 ) 3.50 — Balance, April 30, 2024, 2023 and 2022 — — —
Summary of Changes in Finder's Warrants	The changes in the finder’s warrants for the years ended April 30, 2024, 2023 and 2022 are as follows: Number of Weighted average Weighted average life Balance, April 30, 2022 130,111 21.59 3.77 Exercised — — — Balance, April 30, 2023 130,111 22.77 2.77 Issued 56,650 1.37 4.61 Exercised — — — Balance, April 30, 2024 186,761 16.44 2.62
Details of Finder's Warrants Outstanding	Details of the finder’s warrants outstanding as at April 30, 2024 are as follows: Expiry Date Exercise price Remaining life Warrants February 3, 2026 (1) 23.00 1.76 130,111 December 8, 2028 (2) 1.37 4.61 56,650 (1) Exercise price of U.S.$ 16.81 . The figure in the table above is translated at the April 30, 2024 rate. (2) Exercise price of U.S.$ 1.00 . The figure in the table above is translated at the April 30, 2024 rate.

Employee Remuneration (Tables)

Employee Remuneration (Tables)	12 Months Ended
	Apr. 30, 2024
Disclosure of employee benefits expenses [abstract]
Summary of Expenses Recognized for Employee Benefits	Expenses recognized for employee benefits for the years ended April 30, 2024, 2023 and 2022 are detailed below: (in thousands) 2024 2023 2022 Wages, salaries 10,733 10,433 8,600 Employee benefits 938 926 798 Payroll taxes 774 939 714 Severance 60 194 8 Share-based payments 1,535 1,943 3,083 14,040 14,435 13,203

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Apr. 30, 2024
Related party transactions [abstract]
Schedule of Schedule of Compensation For Key Management	(in thousands) 2024 2023 2022 Salaries and other short-term benefits 2,454 2,632 2,531 Severance (included in salaries) 60 183 8 Share-based payments expense 928 986 1,388 Director compensation (included in salaries) 343 335 355 3,785 4,136 4,282

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Apr. 30, 2024
Disclosure of detailed information about financial instruments [abstract]
Schedule of Details of Amounts Receivable and Allowances for Credit Losses	Details of amounts receivable and allowance for credit losses as of April 30, 2024, 2023 and 2022 are as follows: (in thousands) 2024 2023 2022 Amounts receivable 3,819 3,280 2,539 Allowance for credit losses ( 29 ) ( 33 ) ( 36 ) Amounts receivable, net 3,790 3,247 2,503
Summary of Classification and Measurement of Financial Assets and Liabilities	At April 30, 2024, the Company is exposed to currency risk through the following assets and liabilities denominated in US dollars and Euros: Euros US Dollars (in thousands) (€) (U.S.$) Cash 784 551 Amounts receivable 1,847 568 2,631 1,119 Accounts payable and accrued liabilities ( 1,344 ) ( 1,258 ) Deferred acquisition payments ( 193 ) — Leases ( 882 ) — ( 2,419 ) ( 1,258 ) Net 212 ( 139 )
Schedule of Contractual Cash Flow Requirements	Contractual cash flow requirements as of April 30, 2024 were as follows: < 1 1 - 2 2 - 5 >5 Total (in thousands) $ $ $ $ $ Accounts payable and accrued liabilities 4,372 — — — 4,372 Leases 2,444 2,411 6,914 5,763 17,532 Total 6,816 2,411 6,914 5,763 21,904

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Apr. 30, 2024
Classes of current inventories [abstract]
Summary of Detailed Information About Inventories	Inventories as of April 30, 2024, 2023 and 2022 consist of the following: (in thousands) 2024 2023 Supplies and parts 1,734 1,344 Antibodies 190 206 Work in process 215 510 2,139 2,060 For the years ended April 30, 2024, 2023 and 2022, inventory write-offs amounted to nil , $ 0.3 million, and nil , respectively. These write-offs were primarily due to obsolescence and changes in market conditions affecting the net realizable value of the inventory.

Segmented Information and Eco_2

Segmented Information and Economic Dependence (Tables)	12 Months Ended
	Apr. 30, 2024
Disclosure of operating segments [abstract]
Summary of Geographical Segments	The Company’s revenues are allocated to geographic regions for the year ended April 30, 2024, 2023 and 2022 as follows: Years ended Revenue by Region 2024 2023 2022 United States of America 12,556 9,365 6,816 Europe 10,867 9,450 9,429 Canada 389 618 572 Australia 482 630 1,540 Other 224 602 1,007 24,518 20,665 19,364 The Company’s non-current assets are allocated to geographic regions as of April 30, 2024, 2023 and 2022 as follows: Non-Current Assets 2024 2023 2022 North America - Corporate 80 89 76 North America 4,138 1,025 1,481 Belgium 22,261 40,406 41,355 Netherlands 22,022 19,501 13,265 48,501 61,021 56,177 Geographic segmentation of the Company’s net income (loss) for the year ended April 30, 2024, 2023 and 2022 is as follows: Years ended Net Income (Loss) by Region 2024 2023 2022 North America - Corporate ( 7,846 ) ( 8,422 ) ( 9,340 ) North America ( 449 ) ( 12,601 ) ( 11,424 ) Belgium ( 20,071 ) ( 7,024 ) ( 215 ) Netherlands 1,189 1,487 4,270 ( 27,177 ) ( 26,560 ) ( 16,709 ) Geographic segmentation of the interest and accretion, and amortization and depreciation for the year ended April 30, 2024, 2023 and 2022 is as follows: Years ended Interest and accretion (in thousands) 2024 2023 2022 North America - Corporate 4 39 258 North America 231 19 51 Belgium — 20 3 Netherlands 619 318 107 854 396 419 Years ended Amortization and depreciation (in thousands) 2024 2023 2022 North America - Corporate 11 14 56 North America 687 720 778 Belgium 2,422 2,543 — Netherlands 2,615 3,408 2,935 5,735 6,685 3,769
Summary of Revenues Allocated According to Revenue Types	The Company’s revenues are allocated according to revenue types for the year ended April 30, 2024, 2023 and 2022 as follows: Years ended Revenue Allocation 2024 2023 2022 Project revenue 22,235 18,677 17,356 Product sales revenue 2,035 1,747 1,652 Cryostorage revenue 248 241 356 24,518 20,665 19,364

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Apr. 30, 2024
Statement of cash flows [abstract]
Summary of Non-cash Investing and Financing Transactions	Non-cash investing and financing transactions (in thousands) April 30, April 30, April 30, Acquisition of building and equipment by lease 7,826 7,593 312 Settlement of convertible debentures — 1,315 304 Fair value of shares issued pursuant to deferred acquisition payment to IPA Europe — — 503
Summary of Changes in Liabilities Arose From Financing Activities	The following changes in liabilities arose from financing activities: Non-cash changes (in thousands) April 30, Cash Flows Acquisition Settlement Accretion Foreign April 30, Deferred acquisition payments 649 ( 146 ) — ( 294 ) 19 56 284 Leases 7,267 ( 1,339 ) 7,593 — — 160 13,681 Total 7,916 ( 1,485 ) 7,593 ( 294 ) 19 216 13,965 Non-cash changes (in thousands) April 30, Cash Flows Acquisition Settlement Accretion Foreign April 30, Deferred acquisition payments 1,237 ( 592 ) — — 27 ( 23 ) 649 Convertible debentures 1,312 — — ( 1,315 ) 3 — — Leases 1,455 ( 1,337 ) 7,593 — — ( 444 ) 7,267 Total 4,004 ( 1,929 ) 7,593 ( 1,315 ) 30 ( 467 ) 7,916 Non-cash changes (in thousands) April 30, Cash Flows Acquisition Debt forgiven Accretion Foreign April 30, Deferred acquisition payments 498 — 1,248 ( 503 ) — ( 6 ) 1,237 Convertible debentures 1,531 — — ( 304 ) 85 — 1,312 Leases 1,926 ( 962 ) 533 — — ( 42 ) 1,455 Total 3,955 ( 962 ) 1,781 ( 807 ) 85 ( 48 ) 4,004

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Apr. 30, 2024
Disclosure Of Income Taxes [Abstract]
Summary of Differences and Related Tax Effects	Income tax expense differs from the amount that would be computed by applying the federal and provincial statutory tax rates of (2024 – 27 %, 2023 – 27 %, and 2022 – 27 %) to the earnings before income taxes. The reasons for the differences and related tax effects are as follows: 2024 2023 2022 $ $ $ Earnings (loss) before income taxes ( 28,703 ) ( 27,752 ) ( 15,848 ) Income taxes (recovery) on earnings before income taxes, at above basic rate ( 7,750 ) ( 7,493 ) ( 3,627 ) Increase (decrease) in taxes resulting from: Nondeductible expenses 1 8 322 Estimated SR&ED ITC ( 166 ) ( 198 ) — Effects of tax rate change and foreign exchange — 209 12 Deferred income tax asset recognized — — ( 138 ) Tax rate difference by jurisdiction 588 948 ( 359 ) Tax benefits not recognized 3,072 4,885 4,651 Impairment loss 2,790 602 — Prior year tax assessments and adjustments ( 183 ) ( 420 ) — Other 122 267 — Income taxes (recovery) ( 1,526 ) ( 1,192 ) 861 2024 2023 2022 $ $ $ Current income taxes 177 ( 242 ) 1,390 Deferred income taxes (recovery) ( 1,703 ) ( 950 ) ( 529 ) Income taxes (recovery) ( 1,526 ) ( 1,192 ) 861
Summary of Temporary Differences to Deferred Income Tax Assets and Liabilities	Temporary differences give rise to the following deferred income tax assets and liabilities: 2024 2023 2022 $ $ $ Other tax pools 31 ( 20 ) Capital assets net of lease liabilities 16 ( 61 ) 8 Inventory and intangible assets ( 5,841 ) ( 7,631 ) ( 8,093 ) Recognized deferred income tax liabilities ( 5,825 ) ( 7,661 ) ( 8,105 ) 2024 2023 2022 $ $ $ Non-capital losses carried forward (expire from 2027 to 2040 ) 13,424 9,930 10,514 Other tax pools — — 1,373 Capital losses carried forward 295 295 194 Capital assets net of lease liabilities — 20 13 Financing costs 402 746 979 Less: unrecognized deferred income tax asset ( 14,121 ) ( 10,991 ) ( 13,073 ) Unrecognized deferred income tax liabilities — — —

Nature of Operations - Addition

Nature of Operations - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
Disclosure Of Nature Of Operations [Abstract]
Net losses	$ 27,177	$ 26,560	$ 16,709
Accumulated deficit	100,265	$ 73,088
Cash on hand	$ 3,500

Basis of Presentation - Summary

Basis of Presentation - Summary of Subsidiaries which are Wholly Owned and Subject to Control (Details)	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
ImmunoPrecise Antibodies (Canada) Ltd.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	ImmunoPrecise Antibodies (Canada) Ltd.
Equity Interest percentage	100%	100%	100%
Country of Incorporation	Canada
Functional Currency	Canadian dollar
ImmunoPrecise Antibodies (USA) Ltd. ("IPA USA")
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	ImmunoPrecise Antibodies (USA) Ltd. ("IPA USA")
Equity Interest percentage	100%	100%	100%
Country of Incorporation	USA
Functional Currency	US dollar
ImmunoPrecise Antibodies (N.D.) Ltd.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	ImmunoPrecise Antibodies (N.D.) Ltd.
Equity Interest percentage	100%	100%	100%
Country of Incorporation	USA
Functional Currency	US dollar
ImmunoPrecise Antibodies (MA) LLC
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	ImmunoPrecise Antibodies (MA) LLC
Equity Interest percentage	100%	100%	100%
Country of Incorporation	USA
Functional Currency	US dollar
Talem Therapeutics LLC ("Talem")
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	Talem Therapeutics LLC ("Talem")
Equity Interest percentage	100%	100%	100%
Country of Incorporation	USA
Functional Currency	US dollar
ImmunoPrecise Netherlands B.V.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	ImmunoPrecise Netherlands B.V.
Equity Interest percentage	100%	100%	100%
Country of Incorporation	Netherlands
Functional Currency	Euro
ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe")
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe")
Equity Interest percentage	100%	100%	100%
Country of Incorporation	Netherlands
Functional Currency	Euro
BioStrand B.V.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	BioStrand B.V.
Equity Interest percentage	100%	100%	100%
Country of Incorporation	Belgium
Functional Currency	Euro
Idea Family B.V.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	Idea Family B.V.
Equity Interest percentage	100%	100%	100%
Country of Incorporation	Belgium
Functional Currency	Euro
BioKey B.V.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	BioKey B.V.
Equity Interest percentage	100%	100%	100%
Country of Incorporation	Belgium
Functional Currency	Euro
BioClue B.V.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	BioClue B.V.
Equity Interest percentage	100%	100%	100%
Country of Incorporation	Belgium
Functional Currency	Euro
ImmunoPrecise Antibodies (Quebec), Ltd.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	ImmunoPrecise Antibodies (Quebec), Ltd.
Equity Interest percentage	100%	100%	100%
Country of Incorporation	Canada
Functional Currency	Canadian dollar
9438-9244 Quebec, Inc
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	9438-9244 Quebec, Inc.
Equity Interest percentage	100%	100%	100%
Country of Incorporation	Canada
Functional Currency	Canadian dollar

Significant Accounting Polici_4

Significant Accounting Policies - Summary of Classification and Measurement of Financial Assets and Liabilities (Details)	12 Months Ended
	Apr. 30, 2024
Cash
Disclosure Of Financial Instruments [Line Items]
Financial assets, Classification and measurement IFRS 9	Amortized cost
Amounts Receivable
Disclosure Of Financial Instruments [Line Items]
Financial assets, Classification and measurement IFRS 9	Amortized cost
Investment
Disclosure Of Financial Instruments [Line Items]
Financial assets, Classification and measurement IFRS 9	FVTPL
Accounts Payable and Accrued Liabilities
Disclosure Of Financial Instruments [Line Items]
Financial liabilities, Classification and measurement IFRS 9	Amortized cost
Convertible Debentures
Disclosure Of Financial Instruments [Line Items]
Financial liabilities, Classification and measurement IFRS 9	Amortized cost
Deferred Acquisition Payments
Disclosure Of Financial Instruments [Line Items]
Financial liabilities, Classification and measurement IFRS 9	Amortized cost

Significant Accounting Polici_5

Significant Accounting Policies - Summary of Revenue Recognized Over Time Versus at Point in Time (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
Disclosure of detailed information about financial instruments [line items]
Revenue	$ 24,518	$ 20,665	$ 19,364
Point-in-Time
Disclosure of detailed information about financial instruments [line items]
Revenue	22,235	18,677	17,356
Over Time
Disclosure of detailed information about financial instruments [line items]
Revenue	$ 2,283	$ 1,988	$ 2,008

Significant Accounting Polici_6

Significant Accounting Policies - Schedule of Estimated Term of Asset (Details)	12 Months Ended
	Apr. 30, 2024
Lab Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Basis	Straight line
Term	5 years
Furniture and Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Basis	Straight line
Term	5 years
Computer Hardware
Disclosure Of Property Plant And Equipment [Line Items]
Basis	Straight line
Term	2 years
Building
Disclosure Of Property Plant And Equipment [Line Items]
Basis	Straight line
Term	Remaining term of the property lease
Automobile
Disclosure Of Property Plant And Equipment [Line Items]
Basis	Straight line
Term	Remaining term of the automobile lease
Leasehold Improvements
Disclosure Of Property Plant And Equipment [Line Items]
Basis	Straight line
Term	Shorter of useful life and remaining term of the lease plus the first renewal option
Computer Software
Disclosure Of Property Plant And Equipment [Line Items]
Basis	Straight line
Term	1 year

Significant Accounting Polici_7

Significant Accounting Policies - Summary of Amortization of Intangible Assets with Finite Lives (Details)	12 Months Ended
	Apr. 30, 2024
Internally generated development costs
Disclosure of detailed information about intangible assets [line items]
Basis	Straight line
Term	5 years
Intellectual property
Disclosure of detailed information about intangible assets [line items]
Basis	Straight line
Intellectual property | Bottom of range [member]
Disclosure of detailed information about intangible assets [line items]
Term	10 years
Intellectual property | Top of range [member]
Disclosure of detailed information about intangible assets [line items]
Term	15 years
Proprietary processes
Disclosure of detailed information about intangible assets [line items]
Basis	Straight line
Term	5 years
Certifications
Disclosure of detailed information about intangible assets [line items]
Basis	Straight line
Term	1 year
Customer list
Disclosure of detailed information about intangible assets [line items]
Basis	Straight line
Term	2 years

Significant Accounting Polici_8

Significant Accounting Policies - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
Disclosure of detailed information about intangible assets [line items]
Impairment of long-lived assets, description	The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by comparison of their carrying amount to the recoverable amount. The recoverable amount is the higher of the fair value less costs of disposal or the value in use. Value in use is determined by the present value of the future cash flows from the asset. If the recoverable amount is less than the carrying amount, then there is impairment. Where an impairment loss exists, the portion of the carrying amount exceeding the recoverable amount is recorded as an expense immediately. Assets that have been impaired in prior periods are tested for possible reversal of impairment whenever events or changes in circumstance indicate that the impairment has reversed. If the impairment has reversed, the carrying amount of the asset is increased to its recoverable amount but not beyond the carrying amount that would have been determined had no impairment loss been recognized for the asset in prior periods. The reversal is recognized in profit or loss immediately.
Impairment of intangible assets charge	$ 3,870	$ 0	$ 0
Impairment of goodwill	11,161	2,460	$ 0
BioStrand
Disclosure of detailed information about intangible assets [line items]
Impairment of intangible assets charge	3,900
Impairment of goodwill	$ 11,200	$ 2,500

Critical Accounting Estimates_2

Critical Accounting Estimates And Judgments - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
Disclosure Of Critical Accounting Estimates And Judgments [Line Items]
Goodwill	$ 7,687	$ 19,171
Impairment of goodwill	11,161	2,460	$ 0
Oss
Disclosure Of Critical Accounting Estimates And Judgments [Line Items]
Goodwill	3,100	3,100
Utrecht
Disclosure Of Critical Accounting Estimates And Judgments [Line Items]
Goodwill	4,600	4,700
Biostrand
Disclosure Of Critical Accounting Estimates And Judgments [Line Items]
Goodwill		11,400
Impairment of goodwill	$ 11,200	$ 2,500

Acquisition of Biostrand - Addi

Acquisition of Biostrand - Additional Information (Detail) $ in Thousands, € in Millions			12 Months Ended
	Apr. 13, 2022 CAD ($) shares	Apr. 13, 2022 EUR (€)	Apr. 30, 2024 CAD ($)	Apr. 30, 2023 CAD ($)	Apr. 30, 2022 CAD ($) shares	Apr. 30, 2022 EUR (€)	Apr. 30, 2022 EUR (€) shares	Apr. 13, 2022 EUR (€) shares
Disclosure of detailed information about business combination [line items]
Net income (loss)			$ (27,177)	$ (26,560)	$ (16,709)
Amortization on the intangible assets			$ 2,968	$ 4,414	2,013
BioStrand B.V. [Member]
Disclosure of detailed information about business combination [line items]
Cash paid at the time or acquisition	$ 3,700							€ 2.7
Transaction costs					700
Fair value of common shares issued	$ 29,126
Net income (loss)					200
Deferred cash payment					$ 100	€ 1
Intellectual property assets useful life					15 years	15 years
BioStrand B.V. [Member] | Escrow Agreement [Member] | Tranche One [Member]
Disclosure of detailed information about business combination [line items]
Percentage of shares to be released to vendors					15%		15%
BioStrand B.V. [Member] | Escrow Agreement [Member] | Tranche Two [Member]
Disclosure of detailed information about business combination [line items]
Percentage of shares to be released to vendors					20%		20%
BioStrand B.V. [Member] | Escrow Agreement [Member] | Tranche Three [Member]
Disclosure of detailed information about business combination [line items]
Percentage of shares to be released to vendors					65%		65%
BioStrand B.V. [Member] | Ninety Days [Member]
Disclosure of detailed information about business combination [line items]
Period of deferred cash payments	90 days	90 days
Deferred cash payment	$ 700	€ 0.5
BioStrand B.V. [Member] | Three Years [Member]
Disclosure of detailed information about business combination [line items]
Period of deferred cash payments	3 years	3 years
Deferred cash payment	$ 600	€ 0.5
BioStrand B.V. [Member] | Ordinary shares [member]
Disclosure of detailed information about business combination [line items]
Number of common shares issued | shares	4,077,774				4,077,774		4,077,774	4,077,774
Fair value of common shares issued					$ 29,100		€ 21.3

Acquisition of Biostrand - Summ

Acquisition of Biostrand - Summary of Allocated Purchase Price (Detail) - BioStrand B.V. [Member] $ in Thousands	Apr. 13, 2022 CAD ($)
Disclosure of detailed information about business combination [line items]
Cash	$ 4,985
Common shares of the Company	29,126
Fair value of consideration	34,111
Cash	36
Amounts receivable	80
Unbilled revenue	8
Equipment and right-of-use assets	247
Intellectual property (not deductible for tax purposes)	28,459
Proprietary processes (not deductible for tax purposes)	391
Goodwill (not deductible for tax purposes)	12,658
Accounts payable and accrued liabilities assumed	(342)
Deferred revenue	9
Leases	(223)
Deferred income tax liability	(7,212)
Total net assets acquired and liabilities assumed	$ 34,111

Acquisition of Biostrand - Su_2

Acquisition of Biostrand - Summary of Changes in Value of Subsequent Payments (Detail) - BioStrand B.V. [Member] - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023
Disclosure of detailed information about business combination [line items]
Beginning balance	$ 717	$ 1,305
Foreign exchange	(12)	45
Accretion	19	27
Working capital adjustment		(68)
Disposal	(294)
Deferred acquisition payment	(146)	(592)
Ending balance	284	$ 717
Less: Current portion	$ (284)

Property and Equipment - Summar

Property and Equipment - Summary of Changes in the Value of Property and Equipment (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	$ 10,392
Ending balance	16,696	$ 10,392
Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	16,742	9,206
Additions	9,257	8,924
Completion of work-in-process		0
Disposals	(4,723)	(2,088)
Foreign exchange	(236)	700
Ending balance	21,040	16,742
Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(6,350)	(5,647)
Depreciation	2,791	2,271
Disposals	4,694	1,841
Foreign exchange	(103)	273
Ending balance	(4,344)	(6,350)
Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	10,392
Ending balance	16,696	10,392
Computer Hardware | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	288	136
Additions	56	138
Completion of work-in-process		0
Disposals	(111)	(3)
Foreign exchange	(4)	17
Ending balance	229	288
Computer Hardware | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(157)	(70)
Depreciation	101	84
Disposals	110	3
Foreign exchange	(2)	6
Ending balance	(146)	(157)
Computer Hardware | Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	131
Ending balance	83	131
Furniture and Equipment | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	53	35
Additions	0	0
Completion of work-in-process		0
Disposals	(31)	0
Foreign exchange	(1)	18
Ending balance	21	53
Furniture and Equipment | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(33)	(29)
Depreciation	4	3
Disposals	31	0
Foreign exchange	0	1
Ending balance	(6)	(33)
Furniture and Equipment | Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	20
Ending balance	15	20
Computer Software | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	50	47
Additions	0	0
Completion of work-in-process		0
Disposals	(49)	0
Foreign exchange	(1)	3
Ending balance	0	50
Computer Software | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(50)	(47)
Depreciation	0	0
Disposals	49	0
Foreign exchange	(1)	3
Ending balance	0	(50)
Computer Software | Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	0
Ending balance	0	0
Building | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	9,085	2,586
Additions	7,826	7,593
Completion of work-in-process		0
Disposals	(1,634)	(1,290)
Foreign exchange	(133)	196
Ending balance	15,144	9,085
Building | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(1,752)	(1,736)
Depreciation	1,723	1,109
Disposals	1,606	1,274
Foreign exchange	(38)	181
Ending balance	(1,831)	(1,752)
Building | Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	7,333
Ending balance	13,313	7,333
Automobile | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	167	239
Additions	1	0
Completion of work-in-process		0
Disposals	0	(95)
Foreign exchange	(3)	23
Ending balance	165	167
Automobile | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(57)	(46)
Depreciation	56	58
Disposals	0	57
Foreign exchange	(1)	10
Ending balance	(112)	(57)
Automobile | Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	110
Ending balance	53	110
Leasehold Improvements | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	626	353
Additions	27	101
Completion of work-in-process		166
Disposals	(344)	0
Foreign exchange	(2)	6
Ending balance	307	626
Leasehold Improvements | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(388)	(348)
Depreciation	58	40
Disposals	344	0
Foreign exchange	0	0
Ending balance	(102)	(388)
Leasehold Improvements | Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	238
Ending balance	205	238
Lab Equipment | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	6,473	5,672
Additions	1,316	1,064
Completion of work-in-process		0
Disposals	(2,554)	(700)
Foreign exchange	(92)	437
Ending balance	5,143	6,473
Lab Equipment | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(3,913)	(3,371)
Depreciation	849	977
Disposals	2,554	507
Foreign exchange	(61)	72
Ending balance	(2,147)	(3,913)
Lab Equipment | Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	2,560
Ending balance	2,996	2,560
WIP - Leasehold Improvements | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	0	138
Additions	31	28
Completion of work-in-process		(166)
Disposals	0	0
Foreign exchange	0	0
Ending balance	31	0
WIP - Leasehold Improvements | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	0	0
Depreciation	0	0
Disposals	0	0
Foreign exchange	0	0
Ending balance	0	0
WIP - Leasehold Improvements | Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	0
Ending balance	$ 31	$ 0

Intangibles Assets - Summary of

Intangibles Assets - Summary of Changes in the Value of the Intangible Assets (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023
Disclosure of detailed information about intangible assets [line items]
Beginning balance	$ 30,925
Ending balance	23,557	$ 30,925
Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	43,616	39,612
Impairments and disposals	(4,063)
Foreign exchange	(739)	4,004
Ending balance	38,814	43,616
Accumulated Amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	12,691	7,222
Amortization	2,968	4,414
Disposals	(193)
Foreign exchange	(209)	1,055
Ending balance	15,257	12,691
Net Book Value
Disclosure of detailed information about intangible assets [line items]
Beginning balance	30,925
Ending balance	23,557	30,925
Internally Generated Development Costs | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	33	33
Impairments and disposals	0
Foreign exchange	0	0
Ending balance	33	33
Internally Generated Development Costs | Accumulated Amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	14	8
Amortization	19	7
Disposals	0
Foreign exchange	0	(1)
Ending balance	33	14
Internally Generated Development Costs | Net Book Value
Disclosure of detailed information about intangible assets [line items]
Beginning balance	19
Ending balance	0	19
Intellectual Properties | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	35,143	31,914
Impairments and disposals	(3,830)
Foreign exchange	(595)	3,229
Ending balance	30,718	35,143
Intellectual Properties | Accumulated Amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	4,775	1,693
Amortization	2,666	2,710
Disposals	0
Foreign exchange	(75)	372
Ending balance	7,366	4,775
Intellectual Properties | Net Book Value
Disclosure of detailed information about intangible assets [line items]
Beginning balance	30,368
Ending balance	23,352	30,368
Proprietary Processes | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	8,103	7,359
Impairments and disposals	(40)
Foreign exchange	(136)	744
Ending balance	7,927	8,103
Proprietary Processes | Accumulated Amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	7,633	5,491
Amortization	216	1,477
Disposals	0
Foreign exchange	(127)	665
Ending balance	7,722	7,633
Proprietary Processes | Net Book Value
Disclosure of detailed information about intangible assets [line items]
Beginning balance	470
Ending balance	205	470
Certifications | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	139	126
Impairments and disposals	0
Foreign exchange	(3)	13
Ending balance	136	139
Certifications | Accumulated Amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	137	0
Amortization	2	128
Disposals	0
Foreign exchange	(3)	9
Ending balance	136	137
Certifications | Net Book Value
Disclosure of detailed information about intangible assets [line items]
Beginning balance	2
Ending balance	0	2
Customer List | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	198	180
Impairments and disposals	(193)
Foreign exchange	(5)	18
Ending balance	0	198
Customer List | Accumulated Amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	132	30
Amortization	65	92
Disposals	(193)
Foreign exchange	(4)	10
Ending balance	0	132
Customer List | Net Book Value
Disclosure of detailed information about intangible assets [line items]
Beginning balance	66
Ending balance	$ 0	$ 66

Goodwill - Schedule of Reconcil

Goodwill - Schedule of Reconciliation of Changes in Goodwill Explanatory (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
Disclosure of reconciliation of changes in goodwill [line items]
Goodwill	$ 19,171
Asset impairment	(11,161)	$ (2,460)	$ 0
Goodwill	7,687	19,171
U Protein IPA Europe And Bio strand [Member]
Disclosure of reconciliation of changes in goodwill [line items]
Goodwill	19,171	19,635
Foreign exchange	(323)	1,996
Asset impairment	(11,161)	(2,460)
Goodwill	$ 7,687	$ 19,171	$ 19,635

Goodwill - Schedule of Tabular

Goodwill - Schedule of Tabular Form of Allocating Goodwill to Cash Generating Units (Details) - CAD ($) $ in Thousands	Apr. 30, 2024	Apr. 30, 2023
Disclosure In Tabular Form Of Allocating Goodwill To Cash Generating Units [Line Items]
Goodwill	$ 7,687	$ 19,171
Goodwill Including Preliminary Value	7,687	19,171
Oss [Member]
Disclosure In Tabular Form Of Allocating Goodwill To Cash Generating Units [Line Items]
Goodwill	3,056	3,109
Utrecht [Member]
Disclosure In Tabular Form Of Allocating Goodwill To Cash Generating Units [Line Items]
Goodwill	4,631	4,710
Bio strand [Member]
Disclosure In Tabular Form Of Allocating Goodwill To Cash Generating Units [Line Items]
Goodwill	$ 0	$ 11,352

Goodwill - Schedule of Informat

Goodwill - Schedule of Information for Individual Asset or Cash generating Unit (Details) - CAD ($) $ in Thousands	Apr. 30, 2024	Apr. 30, 2023
Oss [Member]
Disclosure of information for cash-generating units [line items]
Recoverable amount	$ 5,965	$ 6,723
Terminal growth rates	2.50%	2.50%
Discount rates	22%	21.60%
Utrecht [Member]
Disclosure of information for cash-generating units [line items]
Recoverable amount	$ 12,737	$ 11,405
Terminal growth rates	2.50%	2.50%
Discount rates	19%	18.60%
Bio strand [Member]
Disclosure of information for cash-generating units [line items]
Recoverable amount	$ 14,611	$ 31,546
Terminal growth rates	2.50%	2.50%
Discount rates	45%	33.10%

Goodwill - Additional Informati

Goodwill - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
Disclosure of detailed information about intangible assets [line items]
Term for calculating profit marging for cash generating units	3 years
Impairment loss	$ 11,161	$ 2,460	$ 0
Impairment of intangible assets charge	3,870	0	$ 0
BioStrand
Disclosure of detailed information about intangible assets [line items]
Impairment loss	11,200	$ 2,500
Impairment of intangible assets charge	$ 3,900

Convertible Debentures - Additi

Convertible Debentures - Additional Information (Details) $ in Thousands			12 Months Ended
	May 27, 2020 CAD ($)	May 15, 2020 CAD ($)	Apr. 30, 2024 CAD ($) shares	Apr. 30, 2023 CAD ($)	Apr. 30, 2021 CAD ($)
Convertible Debentures [Line Items]
Convertible debentures conversion price | shares			4.25
Carrying value of new debentures			$ 2,400
Carrying value of equity			2,360
Equity Component
Convertible Debentures [Line Items]
Transaction costs			$ 10
New Debentures
Convertible Debentures [Line Items]
Convertible debentures interest rate	10%	10%	10%
Proceeds from issue of convertible debentures	$ 40	$ 2,590			$ 2,600
Convertible debentures maturity date	May 22, 2022	May 15, 2022
Description of conversion of debt to equity			The Company may force convert the principal amount of the New Debentures at $4.25 per share if the average closing price is equal to or greater than $7.50 for 20 trading days.
Consulting fees			$ 80
Legal and filing fees			30
Transaction costs			100
New Debentures | 10% Convertible Debentures
Convertible Debentures [Line Items]
Carrying value of equity			$ 200
New Debentures | 10% Convertible Debentures | Discounted Cash Flow
Convertible Debentures [Line Items]
Effective interest rate			15%
New Debentures | Equity Component
Convertible Debentures [Line Items]
Accretion expense				$ 3

Convertible Debentures - Summar

Convertible Debentures - Summary of Changes in Value of New Debentures (Details) - CAD ($) $ in Thousands			12 Months Ended
	May 27, 2020	May 15, 2020	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Convertible Debentures [Line Items]
Conversion to shares				$ (1,315)	$ (304)
Equity Component
Convertible Debentures [Line Items]
Transaction costs			$ (10)
New Debentures
Convertible Debentures [Line Items]
Proceeds	$ 40	$ 2,590				$ 2,600
Transaction costs			(100)
New Debentures | Liability Component
Convertible Debentures [Line Items]
Beginning balance			0	103
Accretion expense				0
Conversion to shares				(103)
Ending balance				0	103
New Debentures | Equity Component
Convertible Debentures [Line Items]
Beginning balance			$ 0	1,312
Accretion expense				3
Conversion to shares				(1,315)
Ending balance				$ 0	$ 1,312

Leases - Additional Information

Leases - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
Presentation of Leases for Lessee [Line Items]
Asset impairment			$ 200
Cash outflow for leases	$ 1,300	$ 1,300	$ 1,000
Right-of-use assets	13,366
Initial term of lease		5 years
Renewal option of additional term of lease		5 years
Utrecht
Presentation of Leases for Lessee [Line Items]
Right-of-use assets		$ 7,400
Oss
Presentation of Leases for Lessee [Line Items]
Right-of-use assets	$ 3,700
Initial term of lease	5 years
Victoria
Presentation of Leases for Lessee [Line Items]
Right-of-use assets	$ 3,500
Initial term of lease	10 years

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments Related to Equipment under Finance Lease and Office Lease Obligation (Details) $ in Thousands	Apr. 30, 2024 CAD ($)
Disclosure Of Maturity Analysis Of Finance And Office Lease Payments [Line Items]
Total minimum lease payments	$ 17,532
Less: imputed interest	(3,851)
Total present value of minimum lease payments	13,681
Less: Current portion	(1,563)
Non-current portion	12,118
2025
Disclosure Of Maturity Analysis Of Finance And Office Lease Payments [Line Items]
Total minimum lease payments	2,444
2026
Disclosure Of Maturity Analysis Of Finance And Office Lease Payments [Line Items]
Total minimum lease payments	2,411
2027
Disclosure Of Maturity Analysis Of Finance And Office Lease Payments [Line Items]
Total minimum lease payments	2,408
2028
Disclosure Of Maturity Analysis Of Finance And Office Lease Payments [Line Items]
Total minimum lease payments	2,402
2029
Disclosure Of Maturity Analysis Of Finance And Office Lease Payments [Line Items]
Total minimum lease payments	2,104
More than 5 years
Disclosure Of Maturity Analysis Of Finance And Office Lease Payments [Line Items]
Total minimum lease payments	$ 5,763

Leases - Schedule of Disclosure

Leases - Schedule of Disclosure in Tabular Form of Nature of Companies Leases (Detail)	12 Months Ended
	Apr. 30, 2024
Lab and office facilities
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Number of right of use assets leased	3
No. of leases with extension options	2
No. of leases with options to purchase	0
No. of leases with variable payments linked to an index	2
No. of leases with termination options	2
Automobile
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Number of right of use assets leased	6
No. of leases with extension options	0
No. of leases with options to purchase	0
No. of leases with variable payments linked to an index	6
No. of leases with termination options	6
Weighted average | Lab and office facilities
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Range of remaining term	8 years
Weighted average | Automobile
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Range of remaining term	1 year
Bottom of Range | Lab and office facilities
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Range of remaining term	6 years
Bottom of Range | Automobile
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Range of remaining term	6 months
Top of Range | Lab and office facilities
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Range of remaining term	10 years
Top of Range | Automobile
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Range of remaining term	3 years

Leases - Schedule of Changes in

Leases - Schedule of Changes in the Value of the Right-of-Use Assets (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023
Disclosure of quantitative information about right-of-use assets [line items]
Ending balance	$ 13,366
Cost
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	9,252	$ 3,476
Additions	7,827	7,593
Disposals	(1,634)	(2,072)
Foreign exchange	(136)	255
Ending balance	15,309	9,252
Accumulated Depreciation
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	1,809	2,242
Depreciation	1,779	1,365
Disposals	(1,606)	(1,838)
Foreign exchange	(39)	40
Ending balance	1,943	1,809
Net Book Value
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	7,443
Ending balance		7,443
Building
Disclosure of quantitative information about right-of-use assets [line items]
Ending balance	13,313
Building | Cost
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	9,085	2,586
Additions	7,826	7,593
Disposals	(1,634)	(1,290)
Foreign exchange	(133)	196
Ending balance	15,144	9,085
Building | Accumulated Depreciation
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	1,752	1,736
Depreciation	1,723	1,109
Disposals	(1,606)	(1,274)
Foreign exchange	(38)	181
Ending balance	1,831	1,752
Building | Net Book Value
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	7,333
Ending balance		7,333
Automobile
Disclosure of quantitative information about right-of-use assets [line items]
Ending balance	53
Automobile | Cost
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	167	239
Additions	1
Disposals		(95)
Foreign exchange	(3)	23
Ending balance	165	167
Automobile | Accumulated Depreciation
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	57	46
Depreciation	56	58
Disposals		(57)
Foreign exchange	(1)	10
Ending balance	112	57
Automobile | Net Book Value
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	$ 110
Ending balance		110
Lab Equipment | Cost
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance		651
Disposals		(687)
Foreign exchange		36
Lab Equipment | Accumulated Depreciation
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance		460
Depreciation		198
Disposals		(507)
Foreign exchange		$ (151)

Leases - Schedule of Disclosu_2

Leases - Schedule of Disclosure in Tabular Form Of Expenses Relating to Payments not included (Detail) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023
Presentation of leases for lessee [abstract]
Leases of low value assets	$ 7	$ 40
Variable lease payments	467	215
Measurement of the lease liability	$ 474	$ 255

Share Capital - Additional Info

Share Capital - Additional Information (Details) $ / shares in Units, $ / shares in Units, $ in Thousands, $ in Millions				12 Months Ended
	Feb. 23, 2024 USD ($)	Apr. 13, 2022 CAD ($) shares	May 03, 2021 CAD ($) shares	Apr. 30, 2024 CAD ($) shares	Apr. 30, 2023 CAD ($) shares	Apr. 30, 2023 CAD ($) $ / shares	Apr. 30, 2022 CAD ($) $ / shares shares	Apr. 30, 2024 $ / shares
Disclosure Of Classes Of Share Capital [Line Items]
Shares issued pursuant to option exercise, shares | shares					263,537		188,000
Number of options, Exercised | shares					318,725
Shares issued pursuant to option exercise					$ (716)		$ (612)
Shares issued pursuant to warrant exercise, shares | shares							925,076
Shares issued pursuant to warrant exercise							$ (3,238)
Share-based payments				$ 1,535	1,943		3,083
Number of underwritten public offering shares | shares				1,265,000
Number of shares exercise by underwriter of over allotment option | shares				165,000
Public offering price for each common share | $ / shares								$ 1
Convertible Debentures [Member]
Disclosure Of Classes Of Share Capital [Line Items]
Debt conversion principal debt amount							$ 300
IPA Europe
Disclosure Of Classes Of Share Capital [Line Items]
Shares issued pursuant to deferred payment for acquisition, Number of Shares | shares							41,488
Shares issued pursuant to deferred payment for acquisition							$ 503
Share Capital
Disclosure Of Classes Of Share Capital [Line Items]
Shares issued pursuant to option exercise					$ (1,493)		(1,013)
Shares issued pursuant to warrant exercise							(3,491)
Share Capital | IPA Europe
Disclosure Of Classes Of Share Capital [Line Items]
Shares issued pursuant to deferred payment for acquisition							$ 503
Share Capital | Common Shares
Disclosure Of Classes Of Share Capital [Line Items]
Shares issued pursuant to option exercise, shares | shares					263,537		188,000
Total gross proceeds from exercise of stock options					$ 700		$ 600
Shares issued pursuant to option exercise					$ 800		$ 400
Weighted average share price | (per share)						$ 4.5	$ 7.95
Shares issued pursuant to warrant exercise, shares | shares							925,076
Total gross proceeds from exercise of warrants							$ 3,200
Shares issued pursuant to warrant exercise							$ (300)
Shares issued pursuant to conversion of convertible debentures, Number of Shares | shares					309,877		75,292
Convertible debentures					$ 1,300		$ 300
Debt conversion principal debt amount					1,300	$ 1,300
Share Capital | Common Shares | IPA Europe
Disclosure Of Classes Of Share Capital [Line Items]
Shares issued pursuant to deferred payment for acquisition, Number of Shares | shares			41,488
Shares issued pursuant to deferred payment for acquisition			$ 500
Share Capital | Common Shares | BioStrand [Member]
Disclosure Of Classes Of Share Capital [Line Items]
Shares issued pursuant to deferred payment for acquisition, Number of Shares | shares		4,077,774
Shares issued pursuant to deferred payment for acquisition		$ 29,100
Contributed Surplus
Disclosure Of Classes Of Share Capital [Line Items]
Shares issued pursuant to option exercise					$ 777		401
Shares issued pursuant to warrant exercise							$ 253
Common Shares | Top of Range | At The Market Equity Offering Facility
Disclosure Of Classes Of Share Capital [Line Items]
Common stock aggregate gross sales price	$ 60

Share Capital - Summary of Stoc

Share Capital - Summary of Stock Option Awards (Details) - 12 months ended Apr. 30, 2024 $ / shares in Units, $ in Thousands		CAD ($) shares yr $ / shares	CAD ($) shares yr $ / shares
January 2, 2022 | Directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[1]	January 2, 2022	January 2, 2022
Stock options granted | shares	[1]	28,250	28,250
Exercisable price/option	[1]	$ 6.89
Awarded to	[1]	Directors	Directors
Share price on grant date	[1]	$ 6.89
Dividend yield	[1]	0%	0%
Expected volatility	[1]	77%	77%
Risk- free rate	[1]	1.18%	1.18%
Expected life | yr	[1]	4	4
Fair value | $	[1]	$ 100	$ 100
January 7, 2022 | Officers and employee
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[2]	January 7, 2022	January 7, 2022
Stock options granted | shares	[2]	225,000	225,000
Exercisable price/option	[2]	$ 7.94
Awarded to	[2]	Officers and employees	Officers and employees
Share price on grant date	[2]	$ 7.94
Dividend yield	[2]	0%	0%
Expected volatility	[2]	77%	77%
Risk- free rate	[2]	1.42%	1.42%
Expected life | yr	[2]	5	5
Fair value | $	[2]	$ 1,100	$ 1,100
January 7, 2022 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[2]	January 7, 2022	January 7, 2022
Stock options granted | shares	[2]	113,000	113,000
Exercisable price/option	[2]	$ 7.94
Awarded to	[2]	Employees	Employees
Share price on grant date	[2]	$ 7.94
Dividend yield	[2]	0%	0%
Expected volatility	[2]	77%	77%
Risk- free rate	[2]	1.42%	1.42%
Expected life | yr	[2]	4.7	4.7
Fair value | $	[2]	$ 500	$ 500
January 13, 2022 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[2]	January 13, 2022	January 13, 2022
Stock options granted | shares	[2]	24,000	24,000
Exercisable price/option	[2]	$ 8.3
Awarded to	[2]	Employees	Employees
Share price on grant date	[2]	$ 8.3
Dividend yield	[2]	0%	0%
Expected volatility	[2]	77%	77%
Risk- free rate	[2]	1.43%	1.43%
Expected life | yr	[2]	4.7	4.7
Fair value | $	[2]	$ 100	$ 100
January 13, 2022 | Officer
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[3]	January 13, 2022	January 13, 2022
Stock options granted | shares	[3]	15,000	15,000
Exercisable price/option	[3]	$ 8.3
Awarded to	[3]	Officer	Officer
Share price on grant date	[3]	$ 8.3
Dividend yield	[3]	0%	0%
Expected volatility	[3]	77%	77%
Risk- free rate	[3]	1.43%	1.43%
Expected life | yr	[3]	1	1
Fair value | $	[3]	$ 40	$ 40
March 11, 2022 | Consultant
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[4]	March 11, 2022	March 11, 2022
Stock options granted | shares	[4]	25,000	25,000
Exercisable price/option	[4]	$ 6.35
Awarded to	[4]	Consultant	Consultant
Share price on grant date	[4]	$ 4.67
Dividend yield	[4]	0%	0%
Expected volatility	[4]	76%	76%
Risk- free rate	[4]	1.77%	1.77%
Expected life | yr	[4]	2	2
Fair value | $	[4]	$ 30	$ 30
May 15, 2022 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[2]	May 15, 2022	May 15, 2022
Stock options granted | shares	[2]	80,000	80,000
Exercisable price/option	[2]	$ 5.79
Awarded to	[2]	Employees	Employees
Share price on grant date	[2]	$ 3.79
Dividend yield	[2]	0%	0%
Expected volatility	[2]	77%	77%
Risk- free rate	[2]	2.73%	2.73%
Expected life | yr	[2]	5	5
Fair value | $	[2]	$ 300	$ 300
February 19, 2023 | Directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[1]	February 19, 2023	February 19, 2023
Stock options granted | shares	[1]	29,060	29,060
Exercisable price/option	[1],[5]		$ 4.1
Awarded to	[1]	Directors	Directors
Share price on grant date	[1],[5]		$ 4.1
Dividend yield	[1]	0%	0%
Expected volatility	[1]	77%	77%
Risk- free rate	[1]	3.57%	3.57%
Expected life | yr	[1]	4	4
Fair value | $	[1]	$ 100	$ 100
February 19, 2023 | Officers and employee
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[2]	February 19, 2023	February 19, 2023
Stock options granted | shares	[2]	609,452	609,452
Exercisable price/option	[2],[5]		$ 4.1
Awarded to	[2]	Officers and employees	Officers and employees
Share price on grant date	[2],[5]		$ 4.1
Dividend yield	[2]	0%	0%
Expected volatility	[2]	77%	77%
Risk- free rate	[2]	3.57%	3.57%
Expected life | yr	[2]	5	5
Fair value | $	[2]	$ 2,200	$ 2,200
January 19, 2024 | Directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[6]	January 19, 2024	January 19, 2024
Stock options granted | shares	[6]	240,000	240,000
Exercisable price/option	[5],[6]		$ 1.48
Awarded to	[6]	Directors	Directors
Share price on grant date	[5],[6]		$ 1.48
Dividend yield	[6]	0%	0%
Expected volatility	[6]	77%	77%
Risk- free rate	[6]	3.64%	3.64%
Expected life | yr	[6]	5	5
Fair value | $	[6]	$ 400	$ 400
January 4, 2023 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[6]	January 4, 2023	January 4, 2023
Stock options granted | shares	[6]	8,000	8,000
Exercisable price/option	[5],[6]		$ 1.47
Awarded to	[6]	Employees	Employees
Share price on grant date	[5],[6]		$ 1.47
Dividend yield	[6]	0%	0%
Expected volatility	[6]	77%	77%
Risk- free rate	[6]	3.68%	3.68%
Expected life | yr	[6]	10	10
Fair value | $	[6]	$ 12	$ 12
January 23, 2023 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[6]	January 23, 2023	January 23, 2023
Stock options granted | shares	[6]	8,000	8,000
Exercisable price/option	[5],[6]		$ 1.47
Awarded to	[6]	Employees	Employees
Share price on grant date	[5],[6]		$ 1.47
Dividend yield	[6]	0%	0%
Expected volatility	[6]	77%	77%
Risk- free rate	[6]	3.68%	3.68%
Expected life | yr	[6]	10	10
Fair value | $	[6]	$ 12	$ 12
March 1, 2023 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[6]	March 1, 2023	March 1, 2023
Stock options granted | shares	[6]	8,000	8,000
Exercisable price/option	[5],[6]		$ 1.47
Awarded to	[6]	Employees	Employees
Share price on grant date	[5],[6]		$ 1.47
Dividend yield	[6]	0%	0%
Expected volatility	[6]	77%	77%
Risk- free rate	[6]	3.68%	3.68%
Expected life | yr	[6]	10	10
Fair value | $	[6]	$ 12	$ 12
March 15, 2023 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[6]	March 15, 2023	March 15, 2023
Stock options granted | shares	[6]	4,000	4,000
Exercisable price/option	[5],[6]		$ 1.47
Awarded to	[6]	Employees	Employees
Share price on grant date	[5],[6]		$ 1.47
Dividend yield	[6]	0%	0%
Expected volatility	[6]	77%	77%
Risk- free rate	[6]	3.68%	3.68%
Expected life | yr	[6]	10	10
Fair value | $	[6]	$ 6	$ 6
April 2, 2023 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[6]	April 2, 2023	April 2, 2023
Stock options granted | shares	[6]	4,000	4,000
Exercisable price/option	[5],[6]		$ 1.47
Awarded to	[6]	Employees	Employees
Share price on grant date	[5],[6]		$ 1.47
Dividend yield	[6]	0%	0%
Expected volatility	[6]	77%	77%
Risk- free rate	[6]	3.68%	3.68%
Expected life | yr	[6]	10	10
Fair value | $	[6]	$ 6	$ 6
May 8, 2023 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[6]	May 8, 2023	May 8, 2023
Stock options granted | shares	[6]	4,000	4,000
Exercisable price/option	[5],[6]		$ 1.47
Awarded to	[6]	Employees	Employees
Share price on grant date	[5],[6]		$ 1.47
Dividend yield	[6]	0%	0%
Expected volatility	[6]	77%	77%
Risk- free rate	[6]	3.68%	3.68%
Expected life | yr	[6]	10	10
Fair value | $	[6]	$ 6	$ 6
May 23, 2023 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[6]	May 23, 2023	May 23, 2023
Stock options granted | shares	[6]	4,000	4,000
Exercisable price/option	[5],[6]		$ 1.47
Awarded to	[6]	Employees	Employees
Share price on grant date	[5],[6]		$ 1.47
Dividend yield	[6]	0%	0%
Expected volatility	[6]	77%	77%
Risk- free rate	[6]	3.68%	3.68%
Expected life | yr	[6]	10	10
Fair value | $	[6]	$ 6	$ 6
June 11, 2023 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[6]	June 11, 2023	June 11, 2023
Stock options granted | shares	[6]	8,000	8,000
Exercisable price/option	[5],[6]		$ 1.47
Awarded to	[6]	Employees	Employees
Share price on grant date	[5],[6]		$ 1.47
Dividend yield	[6]	0%	0%
Expected volatility	[6]	77%	77%
Risk- free rate	[6]	3.68%	3.68%
Expected life | yr	[6]	10	10
Fair value | $	[6]	$ 12	$ 12
August 8, 2023 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[6]	August 8, 2023	August 8, 2023
Stock options granted | shares	[6]	4,000	4,000
Exercisable price/option	[5],[6]		$ 1.47
Awarded to	[6]	Employees	Employees
Share price on grant date	[5],[6]		$ 1.47
Dividend yield	[6]	0%	0%
Expected volatility	[6]	77%	77%
Risk- free rate	[6]	3.68%	3.68%
Expected life | yr	[6]	10	10
Fair value | $	[6]	$ 6	$ 6
November 13, 2023 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[6]	November 13, 2023	November 13, 2023
Stock options granted | shares	[6]	8,000	8,000
Exercisable price/option	[5],[6]		$ 1.47
Awarded to	[6]	Employees	Employees
Share price on grant date	[5],[6]		$ 1.47
Dividend yield	[6]	0%	0%
Expected volatility	[6]	77%	77%
Risk- free rate	[6]	3.68%	3.68%
Expected life | yr	[6]	10	10
Fair value | $	[6]	$ 12	$ 12
January 1, 2024 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[6]	January 1, 2024	January 1, 2024
Stock options granted | shares	[6]	12,000	12,000
Exercisable price/option	[5],[6]		$ 1.47
Awarded to	[6]	Employees	Employees
Share price on grant date	[5],[6]		$ 1.47
Dividend yield	[6]	0%	0%
Expected volatility	[6]	77%	77%
Risk- free rate	[6]	3.68%	3.68%
Expected life | yr	[6]	10	10
Fair value | $	[6]	$ 18	$ 18
February 1, 2024 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[6]	February 1, 2024	February 1, 2024
Stock options granted | shares	[6]	4,000	4,000
Exercisable price/option	[5],[6]		$ 1.47
Awarded to	[6]	Employees	Employees
Share price on grant date	[5],[6]		$ 1.47
Dividend yield	[6]	0%	0%
Expected volatility	[6]	77%	77%
Risk- free rate	[6]	3.68%	3.68%
Expected life | yr	[6]	10	10
Fair value | $	[6]	$ 6	$ 6
February 19, 2024 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[6]	February 19, 2024	February 19, 2024
Stock options granted | shares	[6]	12,000	12,000
Exercisable price/option	[5],[6]		$ 1.47
Awarded to	[6]	Employees	Employees
Share price on grant date	[5],[6]		$ 1.47
Dividend yield	[6]	0%	0%
Expected volatility	[6]	77%	77%
Risk- free rate	[6]	3.68%	3.68%
Expected life | yr	[6]	10	10
Fair value | $	[6]	$ 18	$ 18
February 20, 2024 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	[6]	February 20, 2024	February 20, 2024
Stock options granted | shares	[6]	4,000	4,000
Exercisable price/option	[5],[6]		$ 1.47
Awarded to	[6]	Employees	Employees
Share price on grant date	[5],[6]		$ 1.47
Dividend yield	[6]	0%	0%
Expected volatility	[6]	77%	77%
Risk- free rate	[6]	3.68%	3.68%
Expected life | yr	[6]	10	10
Fair value | $	[6]	$ 6	$ 6
[1] Vesting conditions are as follows: one-quarter 3 months after grant date; one-quarter 6 months after grant date; one-quarter 9 months after grant date; and one-quarter 12 months after grant date. Vesting conditions are as follows: one-third 6 months after grant date; one-third 12 months after grant date; and one-third 18 months after grant date. Vesting conditions are as follows: one-third 2 months after grant date; one-third 4 months after grant date; and one-third 6 months after grant date. Vesting conditions are as follows: one-half 3 months after grant date; one-half 6 months after grant date. Priced in U.S.$ Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date .

Share Capital - Summary of St_2

Share Capital - Summary of Stock Option Awards (Parenthetical) (Details)	12 Months Ended
	Apr. 30, 2024
January 2, 2022 | Director [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-quarter 3 months after grant date; one-quarter 6 months after grant date; one-quarter 9 months after grant date; and one-quarter 12 months after grant date.
January 7, 2022 | Officers And Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-third 6 months after grant date; one-third 12 months after grant date; and one-third 18 months after grant date.
January 7, 2022 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-third 6 months after grant date; one-third 12 months after grant date; and one-third 18 months after grant date.
January 13, 2022 | Officers And Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-third 6 months after grant date; one-third 12 months after grant date; and one-third 18 months after grant date.
January 13, 2022 | Officer [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-third 2 months after grant date; one-third 4 months after grant date; and one-third 6 months after grant date.
March 11, 2022 | Consultant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-half 3 months after grant date; one-half 6 months after grant date.
May 15, 2022 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-third 6 months after grant date; one-third 12 months after grant date; and one-third 18 months after grant date.
February 19, 2023 | Officers And Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-third 6 months after grant date; one-third 12 months after grant date; and one-third 18 months after grant date.
February 19, 2023 | Director [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-quarter 3 months after grant date; one-quarter 6 months after grant date; one-quarter 9 months after grant date; and one-quarter 12 months after grant date.
January 19, 2024 | Director [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date.
January 4, 2023 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date.
January 23, 2023 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date.
March 1, 2023 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date.
March 15, 2023 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date.
April 2, 2023 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date.
May 8, 2023 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date.
May 23, 2023 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date.
June 11, 2023 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date
August 8, 2023 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date
November 13, 2023 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date
January 1, 2024 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date
February 1, 2024 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date
February 19, 2024 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date
February 20, 2024 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date

Share Capital - Summary of Chan

Share Capital - Summary of Changes in Stock Option (Details)	12 Months Ended
	Apr. 30, 2024 shares $ / shares	Apr. 30, 2023 shares $ / shares	Apr. 30, 2022 shares $ / shares
Disclosure of classes of share capital [abstract]
Number of options, Outstanding, Beginning balance | shares	1,884,428	1,624,150
Number of options, Granted | shares	332,000	718,512
Number of options, Exercised | shares		(318,725)
Number of option, Expired | shares	(577,335)	(115,174)
Number of options, Forfeited | shares	(117,726)	(24,335)
Number of options, Outstanding | shares	1,521,367	1,884,428	1,624,150
Number of options, Unvested | shares	(460,595)
Number of options, Exercisable | shares	1,060,772
Weighted average exercise price outstanding, Beginning balance | $ / shares	$ 8.03	$ 8.29
Weighted average exercise price, Granted | $ / shares	2.02	5.58
Weighted average exercise price, Exercised | $ / shares		3.27
Weighted average exercise price, Expired | $ / shares	7.15	9.35
Weighted average exercise price, Forfeited | $ / shares	4.15	9.45
Weighted average exercise price outstanding, Ending balance | $ / shares	7.17	$ 8.03	$ 8.29
Weighted average exercise price, Unvested | $ / shares	3.26
Weighted average exercise price, Exercisable | $ / shares	$ 8.87
Weighted average life remaining (years)	3 years 5 months 19 days	3 years 3 months 7 days	2 years 10 months 17 days
Weighted average life remaining (years), Unvested	5 years 3 months
Weighted average life remaining (years), Exercisable	2 years 8 months 12 days

Share Capital - Summary of Opti

Share Capital - Summary of Options Outstanding (Details)		12 Months Ended
		Apr. 30, 2024 shares $ / shares		Apr. 30, 2024 shares $ / shares	Apr. 30, 2023 shares	Apr. 30, 2022 shares
Disclosure Of Classes Of Share Capital [Line Items]
Exercise price | $ / shares		$ 7.17
Remaining life (year)		3 years 5 months 19 days
Options outstanding		1,521,367		1,521,367	1,884,428	1,624,150
Unvested		460,595		460,595
Vested		1,060,772		1,060,772
Option Expiry Date September 1, 2025
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date		September 1, 2025
Exercise price | $ / shares		$ 8.5
Remaining life (year)		1 year 4 months 2 days
Options outstanding		220,000		220,000
Unvested		0		0
Vested		220,000		220,000
Option Expiry Date January 6, 2026
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date		January 6, 2026
Exercise price | $ / shares		$ 20.3
Remaining life (year)		1 year 8 months 8 days
Options outstanding		158,000		158,000
Unvested		0		0
Vested		158,000		158,000
Option Expiry Date May 9, 2026
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[1]	May 9, 2026
Exercise price | (per share)		$ 6.89	[1]	$ 7.72
Remaining life (year)	[1]	1 year 8 months 4 days
Options outstanding	[1]	5,650		5,650
Unvested	[1]	0		0
Vested	[1]	5,650		5,650
Option Expiry Date January 2, 2026
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date		January 2, 2026
Exercise price | $ / shares		$ 7.94
Remaining life (year)		2 years 8 months 8 days
Options outstanding		235,000		235,000
Unvested		0		0
Vested		235,000		235,000
Option Expiry Date January 7, 2027
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date		January 7, 2027
Exercise price | $ / shares		$ 8.3
Remaining life (year)		2 years 8 months 15 days
Options outstanding		16,000		16,000
Unvested		0		0
Vested		16,000		16,000
Option Expiry Date May 15, 2027
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date		May 15, 2027
Exercise price | $ / shares		$ 5.79
Remaining life (year)		3 years 14 days
Options outstanding		72,000		72,000
Unvested		0		0
Vested		72,000		72,000
Option Expiry Date February 19, 2027
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[2]	February 19, 2027
Exercise price | $ / shares	[2]	$ 5.61
Remaining life (year)	[2]	2 years 9 months 21 days
Options outstanding	[2]	7,265		7,265
Unvested	[2]	0		0
Vested	[2]	7,265		7,265
Option Expiry Date February 19, 2028
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[2]	February 19, 2028
Exercise price | $ / shares	[2]	$ 5.61
Remaining life (year)	[2]	3 years 9 months 21 days
Options outstanding	[2]	475,452		475,452
Unvested	[2]	158,484		158,484
Vested	[2]	316,968		316,968
Option Expiry Date January 19, 2034
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[3]	January 19, 2034
Exercise price | (per share)		$ 2.03	[3]	$ 1.48
Remaining life (year)	[3]	4 years 8 months 23 days
Options outstanding	[3]	240,000		240,000
Unvested	[3]	217,778		217,778
Vested	[3]	22,222		22,222
Option Expiry Date January 4, 2033
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[4]	January 4, 2033
Exercise price | $ / shares	[4]	$ 2.01
Remaining life (year)	[4]	8 years 8 months 8 days
Options outstanding	[4]	8,000		8,000
Unvested	[4]	5,667		5,667
Vested	[4]	2,333		2,333
Option Expiry Date January 23, 2033
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[4]	January 23, 2033
Exercise price | $ / shares	[4]	$ 2.01
Remaining life (year)	[4]	8 years 8 months 26 days
Options outstanding	[4]	8,000		8,000
Unvested	[4]	5,667		5,667
Vested	[4]	2,333		2,333
Option Expiry Date March 1, 2033
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[4]	March 1, 2033
Exercise price | $ / shares	[4]	$ 2.01
Remaining life (year)	[4]	8 years 10 months 2 days
Options outstanding	[4]	8,000		8,000
Unvested	[4]	6,000		6,000
Vested	[4]	2,000		2,000
Option Expiry Date March 15, 2033
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[4]	March 15, 2033
Exercise price | $ / shares	[4]	$ 2.01
Remaining life (year)	[4]	8 years 10 months 17 days
Options outstanding	[4]	4,000		4,000
Unvested	[4]	3,000		3,000
Vested	[4]	1,000		1,000
Option Expiry Date April 2, 2033
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[4]	April 2, 2033
Exercise price | $ / shares	[4]	$ 2.01
Remaining life (year)	[4]	8 years 11 months 4 days
Options outstanding	[4]	4,000		4,000
Unvested	[4]	4,000		4,000
Vested	[4]	0		0
Option Expiry Date May 8, 2033
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[4]	May 8, 2033
Exercise price | $ / shares	[4]	$ 2.01
Remaining life (year)	[4]	9 years 10 days
Options outstanding	[4]	4,000		4,000
Unvested	[4]	4,000		4,000
Vested	[4]	0		0
Option Expiry Date May 23, 2033
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[4]	May 23, 2033
Exercise price | $ / shares	[4]	$ 2.01
Remaining life (year)	[4]	9 years 25 days
Options outstanding	[4]	4,000		4,000
Unvested	[4]	4,000		4,000
Vested	[4]	0		0
Option Expiry Date June 11, 2033
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[4]	June 11, 2033
Exercise price | $ / shares	[4]	$ 2.01
Remaining life (year)	[4]	9 years 1 month 13 days
Options outstanding	[4]	8,000		8,000
Unvested	[4]	8,000		8,000
Vested	[4]	0		0
Option Expiry Date August 8, 2033
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[4]	August 8, 2033
Exercise price | $ / shares	[4]	$ 2.01
Remaining life (year)	[4]	9 years 3 months 10 days
Options outstanding	[4]	4,000		4,000
Unvested	[4]	4,000		4,000
Vested	[4]	0		0
Option Expiry Date November 13, 2033
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[4]	November 13, 2033
Exercise price | $ / shares	[4]	$ 2.01
Remaining life (year)	[4]	9 years 6 months 18 days
Options outstanding	[4]	8,000		8,000
Unvested	[4]	8,000		8,000
Vested	[4]	0		0
Option Expiry Date January 1, 2034
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[4]	January 1, 2034
Exercise price | $ / shares	[4]	$ 2.01
Remaining life (year)	[4]	9 years 8 months 4 days
Options outstanding	[4]	12,000		12,000
Unvested	[4]	12,000		12,000
Vested	[4]	0		0
Option Expiry Date February 1, 2034
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[4]	February 1, 2034
Exercise price | $ / shares	[4]	$ 2.01
Remaining life (year)	[4]	9 years 9 months 3 days
Options outstanding	[4]	4,000		4,000
Unvested	[4]	4,000		4,000
Vested	[4]	0		0
Option Expiry Date February 19, 2034
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[4]	February 19, 2034
Exercise price | $ / shares	[4]	$ 2.01
Remaining life (year)	[4]	9 years 9 months 21 days
Options outstanding	[4]	12,000		12,000
Unvested	[4]	12,000		12,000
Vested	[4]	0		0
Option Expiry Date February 20, 2034
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[4]	February 20, 2034
Exercise price | $ / shares	[4]	$ 2.01
Remaining life (year)	[4]	9 years 9 months 25 days
Options outstanding	[4]	4,000		4,000
Unvested	[4]	4,000		4,000
Vested	[4]	0		0
[1] Exercise price of U.S.$ 7.72 . The figure in the table above is translated at the April 30, 2024 rate. Exercise price of U.S.$ 4.10 . The figure in the table above is translated at the April 30, 2024 rate. Exercise price of U.S.$ 1.48 . The figure in the table above is translated at the April 30, 2024 rate. Exercise price of U.S.$ 1.47 . The figure in the table above is translated at the April 30, 2024 rate.

Share Capital - Summary of Op_2

Share Capital - Summary of Options Outstanding (Parenthetical) (Details) - Apr. 30, 2024	$ / shares		$ / shares
Disclosure of classes of share capital [line items]
Exercise price	$ 7.17
Option Expiry Date May 9, 2026
Disclosure of classes of share capital [line items]
Exercise price | (per share)	6.89	[1]	$ 7.72
Option 7 and 8
Disclosure of classes of share capital [line items]
Exercise price			4.1
Option Expiry Date January 19, 2034
Disclosure of classes of share capital [line items]
Exercise price | (per share)	$ 2.03	[2]	1.48
Option 10 to 23
Disclosure of classes of share capital [line items]
Exercise price			$ 1.47
[1] Exercise price of U.S.$ 7.72 . The figure in the table above is translated at the April 30, 2024 rate. Exercise price of U.S.$ 1.48 . The figure in the table above is translated at the April 30, 2024 rate.

Share Capital - Summary of Ch_2

Share Capital - Summary of Changes in Warrants and Finder's Warrants (Details)	12 Months Ended
	Apr. 30, 2024 shares $ / shares	Apr. 30, 2023 shares $ / shares	Apr. 30, 2022 shares $ / shares	Apr. 30, 2021 shares $ / shares
Disclosure Of Classes Of Share Capital [Line Items]
Balance, Number of warrants | shares			878,300
Exercised, Number of warrants | shares			(878,300)
Balance, Number of warrants | shares				878,300
Balance, Weighted average exercise price | $ / shares			$ 3.5
Exercised, Weighted average exercise price | $ / shares			$ 3.5
Balance, Weighted average exercise price | $ / shares				$ 3.5
Weighted average life remaining (years)				10 months 24 days
Finder's Warrants
Disclosure Of Classes Of Share Capital [Line Items]
Balance, Number of warrants | shares	130,111	130,111
Issued, Number of warrants | shares	56,650
Exercised, Number of warrants | shares	0	0
Balance, Number of warrants | shares	186,761	130,111	130,111
Balance, Weighted average exercise price | $ / shares	$ 22.77	$ 21.59
Issued, Weighted average exercise price | $ / shares	1.37
Exercised, Weighted average exercise price | $ / shares	0	0
Balance, Weighted average exercise price | $ / shares	$ 16.44	$ 22.77	$ 21.59
Weighted average life remaining, Issued (years)	4 years 7 months 9 days
Weighted average life remaining (years)	2 years 7 months 13 days	2 years 9 months 7 days	3 years 9 months 7 days

Share Capital - Details of Warr

Share Capital - Details of Warrants and Finder's Warrants Outstanding (Details)		12 Months Ended
		Apr. 30, 2024 shares $ / shares	Apr. 30, 2023 shares	Apr. 30, 2022 shares	Apr. 30, 2021 shares
Disclosure Of Classes Of Share Capital [Line Items]
Warrants outstanding					878,300
Finder's Warrants
Disclosure Of Classes Of Share Capital [Line Items]
Warrants outstanding		186,761	130,111	130,111
Range One | Finder's Warrants
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[1]	Feb. 03, 2026
Exercise price $ | $ / shares	[1]	$ 23
Remaining life (year)	[1]	1 year 9 months 3 days
Warrants outstanding	[1]	130,111
Range Two | Finder's Warrants
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[2]	Dec. 08, 2028
Exercise price $ | $ / shares	[2]	$ 1.37
Remaining life (year)	[2]	4 years 7 months 9 days
Warrants outstanding	[2]	56,650
[1] Exercise price of U.S.$ 16.81 . The figure in the table above is translated at the April 30, 2024 rate. Exercise price of U.S.$ 1.00 . The figure in the table above is translated at the April 30, 2024 rate.

Share Capital - Details of Wa_2

Share Capital - Details of Warrants and Finder's Warrants Outstanding (Parenthetical) (Details) - Finder's Warrants	12 Months Ended
	Apr. 30, 2024 $ / shares
Range One
Disclosure Of Classes Of Share Capital [Line Items]
Warrant exercisable price	$ 16.81
Range Two
Disclosure Of Classes Of Share Capital [Line Items]
Warrant exercisable price	$ 1

Employee Remuneration - Summary

Employee Remuneration - Summary of Expenses Recognized for Employee Benefits (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
Disclosure of employee benefits expenses [abstract]
Wages, salaries	$ 10,733	$ 10,433	$ 8,600
Employee benefits	938	926	798
Payroll taxes	774	939	714
Severance	60	194	8
Share-based payments	1,535	1,943	3,083
Total employee benefits expense	$ 14,040	$ 14,435	$ 13,203

Related Party Transactions - Sc

Related Party Transactions - Schedule of Compensation For Key Management (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
Disclosure of transactions between related parties [abstract]
Salaries and other short-term benefits	$ 2,454	$ 2,632	$ 2,531
Severance (included in salaries)	60	183	8
Share-based payments expense	928	986	1,388
Director compensation (included in salaries)	343	335	355
Related party transaction, due from (to) related party	$ 3,785	$ 4,136	$ 4,282

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - CAD ($) $ in Millions	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
Related party transactions [abstract]
Accrued liabilities related parties current	$ 0.3	$ 0.9	$ 0.4

Capital Management - Additional

Capital Management - Additional Information (Details) - CAD ($) $ in Thousands	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Disclosure of objectives, policies and processes for managing capital [line items]
Shareholders Equity	$ 33,921	$ 57,803	$ 75,285	$ 56,924
Capital Management
Disclosure of objectives, policies and processes for managing capital [line items]
Shareholders Equity	$ 31,400

Financial Instruments - Schedul

Financial Instruments - Schedule of Details of Amounts Receivable and Allowances for Credit Losses (Details) - CAD ($) $ in Thousands	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
Allowances For Doubtful Accounts [Abstract]
Amounts receivable, gross	$ 3,819	$ 3,280	$ 2,539
Allowance for credit losses	(29)	(33)	(36)
Amounts receivable, net	$ 3,790	$ 3,247	$ 2,503

Financial Instruments - Additio

Financial Instruments - Additional Information (Details)	Apr. 30, 2024 CAD ($)
USD
Disclosure Of Financial Instruments [Line Items]
Foreign currency exchange rate	1.3686
Euro
Disclosure Of Financial Instruments [Line Items]
Foreign currency exchange rate	1.468

Financial Instruments - Sched_2

Financial Instruments - Schedule of Assets and Liabilities (Details) € in Thousands, $ in Thousands, $ in Thousands	Apr. 30, 2024 CAD ($)	Apr. 30, 2024 EUR (€)	Apr. 30, 2024 USD ($)	Apr. 30, 2023 CAD ($)	Apr. 30, 2022 CAD ($)	Apr. 30, 2021 CAD ($)
Disclosure Of Financial Instruments [Line Items]
Cash	$ 3,545			$ 8,366	$ 30,047	$ 41,838
Total assets	59,988			77,813
Liabilities	$ (26,067)			$ (20,010)
Currency Risk
Disclosure Of Financial Instruments [Line Items]
Cash		€ 784	$ 551
Amounts receivable		1,847	568
Total assets		2,631	1,119
Accounts payable and accrued liabilities		(1,344)	(1,258)
Deferred acquisition payments		(193)	0
Leases		(882)	0
Liabilities		(2,419)	(1,258)
Net		€ 212	$ (139)

Financial Instruments - Sched_3

Financial Instruments - Schedule of Contractual Cash Flow Requirements (Details) - CAD ($) $ in Thousands	Apr. 30, 2024	Apr. 30, 2023
Disclosure Of Financial Instruments [Line Items]
Total liabilities	$ 26,067	$ 20,010
Liquidity Risk
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	4,372
Leases	17,532
Total liabilities	21,904
Liquidity Risk | Not Later Than One Year
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	4,372
Leases	2,444
Total liabilities	6,816
Liquidity Risk | Later Than One Year and Not Later Than Two Years
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	0
Leases	2,411
Total liabilities	2,411
Liquidity Risk | Later Than Two Years and Not Later Than Five Years
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	0
Leases	6,914
Total liabilities	6,914
Liquidity Risk | More than 5 years
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	0
Leases	5,763
Total liabilities	$ 5,763

Inventories - Summary of Detail

Inventories - Summary of Detailed Information About Inventories (Detail) - CAD ($) $ in Thousands	Apr. 30, 2024	Apr. 30, 2023
Classes of current inventories [abstract]
Supplies and parts	$ 1,734	$ 1,344
Antibodies	190	206
Work in process	215	510
Inventories	$ 2,139	$ 2,060

Inventories - Additional Inform

Inventories - Additional Information (Details) - CAD ($) $ in Millions	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
Write-downs (reversals of write-downs) of inventories [abstract]
Inventory write-offs	$ 0	$ 0.3	$ 0

Commitments - Additional Inform

Commitments - Additional Information (Details) € in Millions	12 Months Ended
	Apr. 30, 2024 EUR (€)
Commitments [Line Items]
Minimum contingent earnout payment	€ 12
BioStrand [Member]
Commitments [Line Items]
Percentage of contingent earnout payment based on EBITDA	20%
Unpaid commitment related to earnout	€ 12

Grant and Subsidy Income - Addi

Grant and Subsidy Income - Additional Information (Details) - EUR (€) € in Millions	3 Months Ended	12 Months Ended
	Jul. 31, 2022	Apr. 30, 2024	Apr. 30, 2023	May 31, 2022
Grant And Subsidy Income [Abstract]
Grant awarded				€ 0.5
Proceeds from grants	€ 0.2
Grant income		€ 0.2	€ 0.2

Segmented Information and Eco_3

Segmented Information and Economic Dependence - Summary of Geographical Segments (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
Disclosure Of Geographical Areas [Line Items]
Revenues	$ 24,518	$ 20,665	$ 19,364
Non-current assets	48,501	61,021	56,177
Net income (loss)	(27,177)	(26,560)	(16,709)
Interest and accretion	854	396	419
Amortization and depreciation	5,735	6,685	3,769
United States of America
Disclosure Of Geographical Areas [Line Items]
Revenues	12,556	9,365	6,816
Europe
Disclosure Of Geographical Areas [Line Items]
Revenues	10,867	9,450	9,429
Canada
Disclosure Of Geographical Areas [Line Items]
Revenues	389	618	572
Australia
Disclosure Of Geographical Areas [Line Items]
Revenues	482	630	1,540
North America
Disclosure Of Geographical Areas [Line Items]
Non-current assets	4,138	1,025	1,481
Net income (loss)	(449)	(12,601)	(11,424)
Interest and accretion	231	19	51
Amortization and depreciation	687	720	778
North America | Corporate
Disclosure Of Geographical Areas [Line Items]
Non-current assets	80	89	76
Net income (loss)	(7,846)	(8,422)	(9,340)
Interest and accretion	4	39	258
Amortization and depreciation	11	14	56
Belgium
Disclosure Of Geographical Areas [Line Items]
Non-current assets	22,261	40,406	41,355
Net income (loss)	(20,071)	(7,024)	(215)
Interest and accretion	0	20	3
Amortization and depreciation	2,422	2,543	0
Netherlands
Disclosure Of Geographical Areas [Line Items]
Non-current assets	22,022	19,501	13,265
Net income (loss)	1,189	1,487	4,270
Interest and accretion	619	318	107
Amortization and depreciation	2,615	3,408	2,935
Other
Disclosure Of Geographical Areas [Line Items]
Revenues	$ 224	$ 602	$ 1,007

Segmented Information and Eco_4

Segmented Information and Economic Dependence - Summary of Revenues Allocated According to Revenue Types (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
Disclosure Of Geographical Areas [Line Items]
Revenues	$ 24,518	$ 20,665	$ 19,364
Project Revenue
Disclosure Of Geographical Areas [Line Items]
Revenues	22,235	18,677	17,356
Product Sales Revenue
Disclosure Of Geographical Areas [Line Items]
Revenues	2,035	1,747	1,652
Cryo Storage Revenue
Disclosure Of Geographical Areas [Line Items]
Revenues	$ 248	$ 241	$ 356

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information - Summary of Non-cash Investing and Financing Transactions (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
Statements [Line Items]
Acquisition of building and equipment by lease	$ 7,826	$ 7,593	$ 312
Settlement of convertible debentures	0	1,315	304
IPA Europe
Statements [Line Items]
Fair value of shares issued pursuant to deferred acquisition payment	$ 0	$ 0	$ 503

Supplemental Cash Flow Inform_4

Supplemental Cash Flow Information - Summary of Changes in Liabilities Arose From Financing Activities (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Beginning balance	$ 7,916	$ 4,004	$ 3,955
Cash Flows	(1,485)	(1,929)	(962)
Non-cash changes, Acquisition	7,593	7,593	1,781
Non-cash changes, Debt forgiven/ Settlement/ Disposal	(294)	(1,315)	(807)
Non-cash changes, Accretion	19	30	85
Non-cash changes, Foreign exchange movements and change in estimates	216	(467)	(48)
Ending balance	13,965	7,916	4,004
Deferred Acquisition Payments
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Beginning balance	649	1,237	498
Cash Flows	(146)	(592)	0
Non-cash changes, Acquisition	0	0	1,248
Non-cash changes, Debt forgiven/ Settlement/ Disposal	(294)	0	(503)
Non-cash changes, Accretion	19	27	0
Non-cash changes, Foreign exchange movements and change in estimates	56	(23)	(6)
Ending balance	284	649	1,237
Convertible Debentures
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Beginning balance	0	1,312	1,531
Cash Flows		0	0
Non-cash changes, Acquisition		0	0
Non-cash changes, Debt forgiven/ Settlement/ Disposal		(1,315)	(304)
Non-cash changes, Accretion		3	85
Non-cash changes, Foreign exchange movements and change in estimates		0	0
Ending balance		0	1,312
Leases
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Beginning balance	7,267	1,455	1,926
Cash Flows	(1,339)	(1,337)	(962)
Non-cash changes, Acquisition	7,593	7,593	533
Non-cash changes, Debt forgiven/ Settlement/ Disposal	0	0	0
Non-cash changes, Accretion	0	0	0
Non-cash changes, Foreign exchange movements and change in estimates	160	(444)	(42)
Ending balance	$ 13,681	$ 7,267	$ 1,455

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details)	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
Disclosure Of Income Taxes [Abstract]
Applicable tax rate	27%	27%	27%

Income Taxes - Summary of Diffe

Income Taxes - Summary of Differences and Related Tax Rate (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
Disclosure Of Income Taxes [Abstract]
Earnings (loss) before income taxes	$ (28,703)	$ (27,752)	$ (15,848)
Income taxes (recovery) on earnings before income taxes, at above basic rate	(7,750)	(7,493)	(3,627)
Nondeductible expenses	1	8	322
Estimated SR&ED ITC	(166)	(198)
Effects of tax rate change and foreign exchange	0	209	12
Deferred income tax asset recognized	0		(138)
Tax rate difference by jurisdiction	588	948	(359)
Tax benefits not recognized	3,072	4,885	4,651
Impairment loss	2,790	602
Prior year tax assessments and adjustments	(183)	(420)
Other	122	267
Income taxes (recovery)	(1,526)	(1,192)	861
Current income taxes	177	(242)	1,390
Deferred income taxes (recovery)	$ (1,703)	$ (950)	$ (529)

Income Taxes - Summary of Tempo

Income Taxes - Summary of Temporary Differences to Deferred Income Tax Assets and Liabilities (Details) - CAD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2022
Disclosure Of Income Taxes [Abstract]
Other tax pools		$ 31	$ (20)
Capital assets net of lease liabilities	$ 16	(61)	8
Inventory and intangible assets	(5,841)	(7,631)	(8,093)
Recognized deferred income tax liabilities	(5,825)	(7,661)	(8,105)
Non-capital losses carried forward (expire from 2027 to 2040)	13,424	9,930	10,514
Other tax pools			1,373
Capital losses carried forward	295	295	194
Capital assets net of lease liabilities		20	13
Financing costs	402	746	979
Less: unrecognized deffered income tax asset	$ (14,121)	$ (10,991)	$ (13,073)

Income Taxes - Summary of Tem_2

Income Taxes - Summary of Temporary Differences to Deferred Income Tax Assets and Liabilities (Parenthetical) (Details)	12 Months Ended
	Apr. 30, 2024
Bottom of Range
Disclosure Of Income Taxes [Line Items]
Non capital loss carried forward expiration period	2027
Top of Range
Disclosure Of Income Taxes [Line Items]
Non capital loss carried forward expiration period	2040

Subsequent Events - Additional

Subsequent Events - Additional Information (Details)		12 Months Ended
	Jul. 16, 2024 USD ($) shares $ / shares	Apr. 30, 2024 shares
Disclosure of non-adjusting events after reporting period [line items]
Conversion price | shares		4.25
A II PN, Ltd | Convertible Debentures
Disclosure of non-adjusting events after reporting period [line items]
Aggregate principal amount of convertible debentures agreed to sell and issue	$ 3,000,000
Percentage of purchase price to aggregate principal amount	95%
Convertible debentures interest rate	8%
Premium percentage on convertible debentures issued	10%
Conversion price | shares	1.16
Market price | $ / shares	$ 0.2
Conversion of convertible debt to equity terms	Subject to certain limitations contained within the Securities Purchase Agreement and the Convertible Debentures, holders of the Convertible Debentures will be entitled to convert the principal amount of, and accrued and unpaid interest, if any, on each Convertible Debenture, in whole or in part, from time to time, into a number of Common Shares at a Conversion Price equal to the lower of (i) U.S.$1.16 per Common Share, or (ii) 95% of the lowest daily VWAP for the Common Shares during the 10 consecutive trading days immediately preceding the conversion date or other date of determination (the “Market Price”), but which Market Price shall not be lower than U.S.$0.20.
A II PN, Ltd | Convertible Debentures | Trance One
Disclosure of non-adjusting events after reporting period [line items]
Aggregate principal amount of convertible debentures agreed to sell and issue	$ 2,000,000
A II PN, Ltd | Convertible Debentures | Trance Two
Disclosure of non-adjusting events after reporting period [line items]
Aggregate principal amount of convertible debentures agreed to sell and issue	$ 1,000,000
A II PN, Ltd | Top of Range | Convertible Debentures
Disclosure of non-adjusting events after reporting period [line items]
Volume-weighted average price | $ / shares	$ 1.16
Conversion price | shares	1.16
A II PN, Ltd | Bottom of Range | Convertible Debentures
Disclosure of non-adjusting events after reporting period [line items]
Principal amount of convertible debentures that holders cannot convert without prior written consent during any consecutive thirty day period	$ 300,000
A II PN, Ltd | On and after November 1, 2024 | Convertible Debentures
Disclosure of non-adjusting events after reporting period [line items]
Premium percentage on convertible debentures issued	10%
Monthly installments payments on convertible debentures principal amount	$ 300,000
A II PN, Ltd | On and after November 1, 2024 | Top of Range | Convertible Debentures
Disclosure of non-adjusting events after reporting period [line items]
Volume-weighted average price | $ / shares	$ 0.2